Factors that influence the function of cardiac adrenoceptors by Allely, Maxine Carole
FACTORS THAT INFLUENCE THE-




THESIS SUBMITTED FOR THE DEGREE OF DOCTOR
OF PHILOSOPHY, UNIVERSITY OF EDINBURGH, 1983.
I HEREBY DECLARE THAT THIS THESIS IS COMPOSED
ENTIRELY BY MYSELF AND THAT THE WORK IS MY OWN;
OTHER PEOPLE'S CONTRIBUTIONS HAVE BEEN
ACKNOWLEDGED WHERE APPROPRIATE.
ABSTRACT
In view of recent reports that both (3,- and p2- adreno¬
ceptors may co-exist in the same organ and subserve
responses in the same direction, we set out to investi¬
gate factors influencing their relative densities and
responses to adrenergic stimuli. We have studied the
effects of sympathectomy on cardiac p-adrenoceptors of
the guinea-pig heart and found both innervated and dis¬
crete sub-populations. While full adrenergic agonists
appear to exert their chrono- and inotropic effects via
the pt-adrenoceptor, salbutamol (previously termed a
partial agonist ) appears to have the dual action of a
prejunctional p2 agonism, hence releasing endogenous
transmitters, and a postjunctional p, antagonism, there¬
by reducing the effects of full adrenergic, agonists in
6-hydroxydopamine - denervated atria. 6-OHDA pretreat-
mant was shown to double guinea-pig cardiac binding
sites for the radioligand (-)125I-pindolol with no
alteration in affinity. There was an increased p, : p2
ratio in both atria and ventricles. The resutls pro¬
duced by radioligand binding studies do not appear to
be directly compatible with the functional adrenoceptor
and may therefore only be termed 'binding sites'.
In the light of conflicting reports on the effects of
thyroid hormones on the responsiveness of the heart to
adrenergic stimuli, we investigated alterations in
canine ECG parameters by thyroid hormones in terms of
effects of (3-blockers. Sotalol, but not propranolol,
was found to decrease the heart rate in the tachy¬
cardia produced by T3 administration. This suggests a
direct thyroid hormone action on the canine myocardium
rather than an enhanced sensitivity to catecholamines
in hyperthyroidism. (3-blocker toxicity studies yielded
the information that neither sotalol nor nadolol
abolished sinus rhythm up to the time of death whereas
propranolol produced a 2 : 1 atrio-ventricular block.
Death due to (3-blocker overdose appears due to resp¬
iratory depressant actions, apparent from the blood
pC02 and p02 levels during (3-blocker infusion, and from
the fact that higher lethal doses were necessary in the
artificially-ventilated animals. These depressant
effects are unrelated to the pharmacokinetic properties
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SECTION I : INTRODUCTION AND REVIEW OF THE LITERATURE
The initial fundamental observations on the specificity
of adrenergic agonists to evoke responses in various
tissues were made as early as 1906 by- Dale when he
found that the physiological effects of certain ergot
alkaloids such as cornutine and sphacelotoxine fell into
two distinct groups. The first group of effects were
those of smooth muscle stimulation eg. arterial, uterine
and iris sphincter contraction while the second group
were those of inhibition of adrenaline-stimulated
sympathetic innervation. In the cat, the increase in
arterial blood pressure in response to adrenaline could
be reversed to a decrease by ergot. This 'adrenaline
reversal' led much later to the conclusion that there
were two receptor pools acting in opposite directions.
This hypothesis was pr~p~sed by Ahlquist (1948) and re¬
placed the earlier idea that different sympathomimetic
amines had either excitatory or inhibitory actions.
This was on the basis of a single rank potency order
for a series of adrenergic agonists i.e. adrenaline >
noradrenaline > methylnoradrenaline > isopropylnor-
adrenaline for vasoconstriction, gut inhibition and
pupil dilatation while an entirely different rank order
of potency of isopropylnoradrenaline > adrenaline >
methylnoradrenaline > adrenaline existed for myocardial
stimulation and vasodilatation. The hypothesis of
adrenoceptor subdivision into a- and (3-subtypes was
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therefore suggested. In 1967, Lands et al investigated
these proposed subtypes more deeply. They suggested a
further subdivision of the ^-adrenoceptor into (3, and
P2 subtypes. Again this was done on the basis of two
distinct patterns of tissue responses emerging to a
series of adrenergic agonists. They found that adrenal¬
ine >y noradrenaline for myocardial stimulation and
lipolysis while adrenaline >> noradrenaline for bronchial
relaxation and vasodilatation. They postulated that the
former was mediated via (3 y -adrenoceptors and the latter
via p2-adrenoceptors. They however noted that the 'pre¬
ference' of the (3.,- and |32-adrenoceptor agonists and
antagonists was not absolute and that multiple effects
may therefore be observed. On this basis, however, it
became accepted that the ^-adrenoceptors of the myo¬
cardium were of the p., subtype and drugs acting on p.,
receptors, and consequently the heart, became termed
'cardioselective' while those adrenoceptors of the air¬
ways were of the p2 subtype and drugs acting predominantly
on p2 adrenoceptors were termed 'bronchioselective'.
Black (personal communication) and Ungar (1979) suggested
a further modification of the system that all pt-adreno¬
ceptors are innervated whereas p2-adrenoceptors may be
widely distributed and more responsive to circulating
catecholamines. In 1971, Sutherland put forward the
concept of the existence of a 'second messenger' which
associates the adrenergic response with an alteration
in the cellular adenylate cyclase concentration. It
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subsequently became accepted that (3,- and (3 2-adrenoceptor
activation is very often associated with adenylate
cyclase activity with a subsequent rise in intracellular
cyclic AMP concentrations whereas some a-adrenoceptor
mediated responses such as those of the human platelet
are associated with a depressed adenylate cyclase
activity with a resultant fall in cyclic AMP levels.
Indeed, it is often now stated that the efficacy of a
^-adrenoceptor agonist may be regarded as its ability
to activate the cellular adenylate cyclase system (Kent
et al, 1979). This adrenoceptor subdivision was
investigated by Carlsson (1972,1977). He found that
selective antagonists inhibited agonist actions in
different orders in the cat heart. He found that met-
oprolol ((3, -selective) antagonised noradrenaline > ad¬
renaline while butoxamine ((32-selective) antagonised
adrenaline > noradrenaline; practolol ((3, -selective)
antagonised the responses to isoprenaline, adrenaline,
noradrenaline and salbutamol to different extents with a
different order being produced by (32-selective H35/25.
His results were best fitted by the hypothesis that both
(3., and (32 subtypes of adrenoceptor coexist in some
tissues such as the cat heart and that responses to
adrenaline and noradrenaline are at least partly mediated
via different ^-adrenoceptors. A further complication
of the adrenoceptor population was suggested by Govier
(1968) in guinea-pig right atria and by Kaumann (1977)
in kitten papillary muscle that when more than 90% of
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the ^-adrenoceptors are occupied by a specific antagonist,
a small component of the remaining positive inotropic
effects of noradrenaline (but not isoprenaline) may be
antagonised by a-adrenoceptor antagonists. This indicates
multiple contributions of several receptor subtypes to
the same response. It was therefore of great interest
to us to investigate the relative numbers of cardiac (3.,
and |32 receptors and whether the subpopulations are
influenced by factors of innervation i.e. are discrete
^-adrenoceptors unaffected by alterations in sympathetic
supply to a tissue whereas innervated receptors are
greatly affected or are the two independent of tissue
innervation?
Often the best way to investigate the physiological and
pharmacological contributions of a system is to 'remove'
it and observe the results. 'Removal' of the sympathetic
nervous system by various means is well-documented as
resulting in a supersensitivity of the organ concerned
to catecholamines. Trendelenberg and Weiner (1962)
described two mechanisms whereby supersensitivity may
develop. The first, a presynaptic supersensitivity, is
seen following the application of cocaine and desipramine
or 24 hours following surgical denervation and they
attributed this to an impairment of noradrenaline up¬
take into the presynaptic nerve terminal leaving a
larger concentration free to evoke a response. The second,
a postsynaptic supersensitivity, is due to an increased
^-adrenoceptor density which occurs 12 - 16 days after
surgical sympathectomy. A denervation supersensitivity
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following degeneration of the sympathetic nervous system
as a result of multiple system atrophy (Shy-Drager
syndrome) is well-documented by Bannister et al (1979,
1981). They found that ^-adrenoceptor density was greatly
increased in lymphocytes in the syndrome with no alter¬
ation of receptor affinity. If lymphocyte receptor
density can be regarded as reflecting the state of the
cardiac adrenoceptors, then this increased receptor
density may account for the increased sensitivity to
isoprenaline observed in the syndrome.
Supersensitivity to catecholamines is widely-reported.
Banerjee et al (1977) demonstrated an increased (3-
adrenoceptor concentration in rat skeletal muscle
following surgical denervation. Broadley and Lumley
(1977) found that reserpine pretreatment shifted both
the rate and tension log dose - response curves of iso¬
lated guinea-pig atria to isoprenaline to the left.
2 +
Since no alteration in tissue response to Ca ions
was demonstrated, it indicated that the resultant super¬
sensitivity was specific for ^-adrenoceptors. They also
found that salbutamol (which produced only a sub-maximal
response in control atria which they termed partial
agonism) also evoked responses at a lower concentration.
Another method of sympathectomy - by 6-hydroxydopamine
(6-OHDA) - has proved popular. Following the suggestion
of Senoh et al (1959) that 6-OHDA may be formed by
dopamine auto-oxidation, further pharmacological
investigations revealed that it could be employed to
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produce a long-term efficient depletion of peripheral
sympathetically-innervated organ catecholamines (Porter
et al, 1963). Mueller et al (1969) reported that 6-OHDA
produced a selective destruction of postganglionic
adrenergic nerve terminals and a long-term depletion of
noradrenaline in sympathetically-innervated organs. In
1974, Kostrzewa and Jacobowitz showed that 6-OHDA was
selectively taken up by the peripheral nervous system
into noradrenergic neurones. This neuronal accumulation
of 6-OHDA appears to be prerequisite'for its destructive
effects (Stone et al, 1964). Since it was demonstrated
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that the accumulation of H-6-0HDA by mouse atria in
vitro that had previously been surgically sympathectomised
was significantly depressed, the actual amount taken up
being identical to that in the presence of desipramine,
and since desipramine inactivates the monoamine uptake
mechanism (Axelrod et al, 1961) it was proposed that in
order to effect a degeneration of the sympathetic
nervous system 6-OHDA is first taken up into nor¬
adrenergic neurones by the active amine pump. This was
supported by Stone et al (1964) who found that imipramine
(also an uptake blocker) prevented noradrenaline
depletion produced by 6-OHDA in mice. After active uptake.
6-OHDA becomes concentrated in the amine storage granules
(as much as 50%) with a concomitant decrease in their
3
noradrenaline content. The granular uptake of H-6-0HDA
was demonstrated in the cat spleen by Thoenen and
Tranzer (1963) who showed at low doses that it could
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be released as a false transmitter. Electron micro¬
scopic studies have revealed that cholinergic neurones,
non-adrenergic neurones, myelinated axons, endothelial
cells and smooth muscle cells are unaffected by 6-OHDA
while the noradrenergic neurone degenerates (Siggins
and Bloom, 1970; Tranzer and Thoenen,* 1967). Twelve
hours to three days following administration of 6-OHDA
to cats and rats, the adrenergic nerve terminals were
found to be in various stages of degeneration. In many
cases, the Schwann cells were seen to engulf the nerve
terminals which appeared to lyse and the plasma membrane
become indiscernible from that of the Schwann cell
( Thoenen, 1972a). The selectivity of neuronal destruction
by 6-OHDA is best seen in organs such as the vas deferens
where cholinergic and adrenergic nerve terminals lie
very close together, often surrounded by the same Schwann
cell, yet the cholinergic nerve remains intact. Thoenen
and Tranzer (1968) stressed that a critical intraneuronal
level of 6-OHDA must be attained to precipitate the
degenerative process. This critical level appears to be
very high in some cases, Jonsson and Sachs (1971)
quoting it as being 1% tissue weight. It is very
interesting to note that the cell bodies of adult rats
and cats display no changes following 6-OHDA treatment
(Thoenen and Tranzer , 1973) even if very high doses are
applies topically or by close-arterial infusion. This
resistance of the cell body is the probable explanation
of the complete recovery and regeneration of the symp¬
athetic nervous system in the adult animal when treatment
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is ceased whereas in newborn animals the entire neurone
is destroyed and the resultant sympathectomy is permanent
(Tranzer et al, 1969). This discrepancy in the severity
of the effects of 6-OHDA in adult and newborn animals
is thought to be due to a shift in the transport eff¬
iciency from the cell body to the periphery during the
animal's development into adulthood (Thoenen, 1972b).
Heusler (1971) showed that thirty minutes following a
toxic dose of 139mg/kg 6-OHDA administered intravenously,
the constrictor response of isolated cat mesenteric
arteries to noradrenaline was significantly depressed
whereas responses to CaCl2 and KC1 were normal indicating
a specific effect of 6-OHDA and not a non-specific
smooth muscle depressant action. If this was repeated
following phentolamine pretreatment, the responses were
as in controls after twenty hours indicating an a-adreno-
ceptor mediated effect of 6-OHDA. However, the time lag
of twenty to forty-eight hours may indicate that there
was covalent bonding of 6-OHDA to the cc-aclrenoceptors
of configurational changes had been produced which dis¬
couraged agonist binding. The specificity of 6-OHDA for
the sympathetic nervous system made it an ideal tool for
the present study to investigate alterations in cardiac
(3-adrenoceptors following sympathectomy both of a
permanent (newborn-treated) and a reversible (adult-
treated) nature. We wished to investigate the effects
of 6-OHDA-induced denervation on cardiac adrenoceptors.
One method of receptor study that has become ever-
increasingly employed in recent years is that of the
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radioligand binding study. When they were introduced, it
was immediately inferred from pharmacological and
physiological studies that a true adrenergic receptor
should demonstrate certain corroborative features in the
binding study to confirm their role .in vivo:
1) binding should demonstrate stereospecificity and (-)
isomers should on the whole be more potent than (+)
isomers.
2) the rank order of potency of drug binding in the
isolated membranes should reflect that in the intact
tissue.
3) binding should be saturable i.e. a finite receptor
population should be demonstrable.
In 1972, Lefkowitz and Levey solubilized a fraction of
cat myocardium that had adenylate cyclase activity and
that would also bind catecholamines in the same order
as in vivo, and would therefore offer a study model. The
production of a suitable radioligand then became the
problem. One of the first ^-adrenoceptor agents to be
used was H-propranolol (Levitski et al, 1974) but it had
such a low specific activity and produced such high non¬
specific binding that it gave only very limited info¬
rmation. In 1974, Lefkowitz et al developed the high-
3
affinity H-dihydroalprenolol which bound to putative
(3-adrenoceptors in the frog erythrocyte membrane, a
similar class of binding site being identified in turkey
erythrocytes by Aurbach et al (1974) using the alternative
125
high affinity label of I-hydroxybenzylpindolol.
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Since neurotransmitter receptors are thought in most
cases to consist of ay least two components - a) the
recognition or binding site and b) a 'translating'
portion to convert the transmitter recognition into an
activation of the second messenger, the effects of
adrenergic agonists on the cyclic AMP*concentration
in vitro should mirror the pharmacological effects in
vivo. Harden et al (1976) showed that the order of
125
potency of an adrenergic agonist series to inhibit I-
hydroxybenzylpindolol binding and to activate cyclic
AMP production were the same and they therefore con¬
cluded that the binding sites visualised by radioligand
binding may be representative of the physiological
receptor. Lefkowitz and Levey (1972) found that adenylate
cyclase activity in their cat myocardial preparation was
not activated until the addition of phosphatidylinositol.
This indicated that the adenylate cyclase system was
located internally from the ^-adrenoceptor (since it
utilised intracellular ATP as a substrate to produce
cyclic AMP) requiring the 'lipophilic bridge' of inositol
to act as a coupling factor. Multiple criteria therefore
appear to be satisfied to equate membrane binding sites
with a physiological adrenoceptor and therefore binding
studies may be regarded as a useful tool for receptor
study provided that certain requirements are met.
Since from the literature it had become apparent that
many factors may be responsible for altering the p-
adrenoceptor mediated response to stimulation by cat¬
echolamines, it would be interesting to investigate a
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further machanism whereby ^-adrenoceptor mediated
responses may be affected - by alteration of thyroid
state. As we planned to investigate a series of p-
adrenoceptor antagonists throughout the study, observing
their effects in changing thyroid state would afford
an opportunity to study the antidysrhythmic properties
of antagonists from all three classes proposed by
Vaughan Williams (1974) :
Class I : these drugs decrease the maximum rate of
depolarisation of cardiac muscle but pro¬
duce no alteration in resting potential.
They restrict entry of the depolarising
current and therefore repolarisation must
proceed further before the ion gates are
open sufficiently for the minimum rate of
rise to produce contraction propagation.
Often termed 'membrane-stabilizing' drugs.
Class II : these drugs are antisympathetic, either by
virtue of producing (3-blockade or by inhib¬
ition of endogenous transmitter release.
Class III : alteration of thyroid state has no effects
on action potential voltages but large
effects on the duration of action potential.
These drugs act to prolong action potential
duration and are often termed 'anti-thyroid'
because they mimic the effects of hypo¬
thyroidism on the myocardium without them¬
selves altering thyroid state or any other
manifestations of thyrotoxicosis.
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None of these classes of drugs are mutually-exclusive,
however, and most drugs overlap in their actions.
It is often unquestioningly accepted that thyroid
hormones increase the sensitivity of cardiac tissues to
(3-adrenergic agonists and that this may be corrected by
epidural blockade (Leak, 1963) indicating an increased
sympathetic activity. Indeed, many of the clinical
manifestations of the thyrotoxic state are consistent
with a hyperadrenergic state, eg. increased heart rate,
02 consumption, cardiac output and ventricular stroke
work. However, in 1971 Levey searched the existing
literature to assess the evidence given for a relationship
between hyperthyroid state and the adrenergic system
shown by an enhanced cardiac sensitivity to infused
catecholamines and by a catecholamine-sensitive adenyl
cyclase system, but he failed. it is therefore
necessary that a further investigation of the relationship
between the adrenergic system and thyroid state be carried
out. In 1969, Wiener et al found that reserpine, a-
methylDopa and guanethidine all reduced the heart rate
and cardiac output in thyrotoxicosis. As left ventricular
tension time is often described as the major determinant
of myocardial 02 consumption, the ratio of LV work :
LV tension time may be used as an index of myocardial
efficiency and this is increased 14% by propranolol
in thyrotoxicosis. In 1977, Williams and Lefkowitz
demonstrated that T3 and T4 treatment of the rat myo¬
cardium resulted in more than doubling of the |3-adreno-
ceptor populations with no alteration in receptor
13
affinity and this was confirmed by Tsai and Chen (1978)
and Tse et al (1980). They proposed that this receptor
concentration increase accounted, at least in part, for
the enhanced responses they observed in hyperthyroidism
to catecholamines, and further that the mechanism for
receptor induction may be mediated by a T4-induced
increase in RNA synthesis. They also found that hyper-
thyroid rats produced more cyclic AMP in response to
isoprenaline. Their findings were given support by
Ciaraldi and Marinetti (1977) who went further to
demonstrate a concurrent decrease in a-adrenoceptor
density with a decrease in affinity. When they extended
the study to include the hypothyroid rat, they found
that the (3-adrenoceptor population was decreased. This
was confirmed in 1978 by Giudicelli who found that
adipocytes taken from thyroidectomised rats had only 1/3
of the ^-adrenoceptor population of euthyroid rats and
that this could be corrected by T3 therapy. These
binding studies consistently suggested that there was
a gross alteration at adrenoceptor level, that these
receptors were functional (indicated by increased cyclic
AMP production) and therefore capable of altering :•
responses to exogenous and endogenous catecholamines.
Wildenthal (1974) found an in vitro mouse heart culture
system where two days exposure to T3 produced no alter¬
ation in rate responses of the atria to theophylline,
glucagon or acetylcholine but where responses to sub-
maximal doses of noradrenaline were significantly
increased. He concluded from this result that high levels
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of T3 do not produce a hypersensitivity to all chrono¬
tropic agents, but only those which produce a chrono¬
tropic effect via the p-adrenoceptor. The specificity of
action was confirmed by Malbon et al (1978) who found
that T4 treatment produced an increase in ^-adrenoceptor
mediated cyclic AMP accumulation in fat cells and
adipose tissues. Hashimoto and Nakashima (1978) showed
that T4 treatment of guinea-pig atria produced an
increase in ^-adrenoceptor mediated inotropic responses.
The correlation of thyroid and adrenergic states is not
always clear-cut, however, McDevitt et al (1978) found
no significant alteration in responsiveness to isopren-
aline in hyperthyroid dogs becoming euthyroid on T3
treatment or, indeed, between the two extremes of hypo-
and hyperthyroid states. Wilson et al (1966) found that
neither oral nor intravenous nethalide ((3-antagonist)
produced any significant alteration in resting heart
rate, blood pressure, cardiac output or 02 consumption
and concluded that the changes in cardiac performance
manifest in hyperthyroidism are not mediated via the
p-adrenergic system. Taylor (1983) showed that T4 had no
effect on noradrenaline (p,) or terbutaline (P2) evoked
relaxation of the guinea-pig trachea. It therefore
appears from the literature that any alterations in
tissue responsiveness to adrenergic agents mediated by
changes in thyroid state may be specific for that given
tissue rather than for all ^-adrenoceptor systems or
subtypes. We thus chose to investigate the effects of a
set of three ^-antagonists in the conscious dog during
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alteration of thyroid state either by carbimazole to
render them hypothyroid or by T3 treatment to mimic
hyperthyroidism. The drugs chosen for the study were
propranolol (Classes I and II antidysrhythmic properties),
sotalol (Classes II and III) and nadolol (Class II and
possibly III). We were particularly interested in Class
III activity since it has been associated with the
thyroid state by Vaughan' Williams (1974). Sotalol is
reported to greatly prolong action potential duration
by a slowing of the terminal phase of cardiac muscle
relaxation and also by producing a small active tension
effect (Kaumann and Olson, 1968). However, the QT
interval used often to assess this is not purely
indicative of the duration of action potential. The action
potential does not follow the same time course throughout
and the QT interval is only indicative of action potential
duration if all ventricular fibres fire synchronously.
Any condition producing asynchronous activation of the
ventricular fibres would therefore produce a QT prolong¬
ation without necessarily affecting action potential
duration. Such conditions as the 'long QT syndrome' are
associated with ventricular dysrhythmias in contrast to
a prolonged action potential duration which, whether
drug- or hypothyroidism-induced, is associated with
stable rhythm. It would therefore be of great interest
to observe Class III activity in altered thyroid states
on the electrophysiological parameters of the dog ECG
and to correlate these with reports in the literature.
Sotalol is reported to be devoid of Class I activity,
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having only 1/300 activity of propranolol as a local
anaesthetic (Singh and Vaughan Williams. 1970). This is
due to sotalol having the same side-chain as isoprenaline
but with an electron-withdrawing group (methyl sulph-
onamide) in the p-position of the aromatic ring and
this reduces local anaesthetic activity and greatly
increases p-blocking potency (Singh and Vaughan Williams,
1971). Nadolol, on the other hand, is a relatively new
(3-blocking drug. It was shown by Vukovich et al (1976)
to produce a reduction or remission in subjects with
frequent ventricular or supraventricular ectopic beats
and other cardiodysrhythmias and since these may be
associated with thyroid dysfunction, we thought it a
useful drug to include in the study. These three blockers
also cover a wide range of pharmacokinetic properties.
Propranolol is approximately 90% plasma protein bound
whereas sotalol is 54% and nadolol only 25-30% bound.
Reports on this do differ though, Patel and Turner
(1981) finding sotalol not to be significantly bound at
all. The drugs also cover a wide range of lipid
solubilities, see Table 10. The study would therefore
be more complete if it was to include a toxicity test
comparing the different pharmacokinetic properties with
the effects on the parameters of the ECG. Sibley et al
(1978) carried out an extensive series of |3-blocker
toxicity tests and found that nadolol was of a very low
toxicity and we wished to see if this result was
confirmed in our hands. The large range of lipid
solubilities of the three drugs afforded us an oppor-
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tunity to attempt to separate their central effects
from their peripheral actions. Since the blood-brain
barrier acts as a lipid membrane (Mayer et al, 1959).
lipid soluble propranolol would be expected to penetrate
it while sotalol would not, nadolol being an intermediate
case. When Mustchin et al (1975) showed that a single
oral dose of 80mg propranolol in humans significantly
depressed the ventilatory response to C02 and also
depressed inspiratory pressure, it was taken that propr¬
anolol possesses central respiratory depressant effects.
We therefore concluded that a model was required to
correlate the p-blocker cardiac and central effects.
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SECTION II : METHODS
1. Preparation of isolated atria.
Guinea-pigs of either sex in the weight range of 300-500g
were killed by a blow to the head and exsanguinated. The
heart was excised and the atria separated (Hashimoto and
Nakashima, 1978; Hughson and Ledsome, 1975). Right atria
were mounted on tissue holders with cotton thread and
allowed to run spontaneously while left atria were
mounted on a combined tissue holder and pacing electrode
and were paced at 210 beats/minute at 2V. Right atria
were suspended in a 10ml organ bath and left atria in a
30ml bath. Both were bathed in Krebs' solution of the milli-
molar concentration : Na+ 141.0; K+ 5.9; Ca2 + 2.6; Mg2 +
I.2; CI" 104.8; H2P04~ 2.2; HC03~ 24.9; S04" 1.2;glucose
II. The solution was gassed with 5% C02 in oxygen and
o -5
maintained at 37 C in the presence of 1.6 x 10 M
— 5
phenoxybenzamine and 10 M metanephrine to inhibit a-
adrenoceptor stimulation and extraneuronal uptake re¬
spectively (Lumley and Broadley, 1977; Kaumann et al,
1978). Isometric contractions were recorded and rate
responses were calculated by an analogue-logic computer
(EAL 380) and tension responses were recorded on an
Electromed devices heat pen recorder.
Preparation of isolated tracheae.
Guinea-pigs of either sex were sacrificed as pre¬
viously described. Tracheae were excised and cut
spirally so as to provide 2 or 3 preparations. Sections
19
of approximately 2cm length were mounted on tissue holders
with cotton threads and suspended in 10ml organ baths in
the conditions as described for atria. Tension was all¬
owed to develop spontaneously, no carbachol was used.
Construction of log dose - response curves.
All preparations were allowed to equilibrate for at least
30mins during which time the bathing medium was changed
several times. A preliminary dose - response curve to
an agonist was constructed until a maximum response was
obtained. This first dose - response curve of the ex¬
periment served to prime the tissue and was not included
in subsequent analysis of data. When rate and tension
levels returned to their pre-drug values, further dose -
response curves to each agonist in duplicate were ob¬
tained. An antagonist was then added to the bath and
incubated for 1 hour before reconstructing dose - response
curves to each of the agonists. Antagonist equilibrium
association constants were calculated from the formula
K = DR - 1
a
B
where DR represents the Resulting dose ratio and B the
antagonist concentration.
Histochemical fluorescence of cardiac monoamines.
To visualise the cardiac monoamines of the control and 6-
OHDA - denervated guinea-pig, the sucrose - phosphate -
glyoxylic acid (SPG) method was used because of its
reproducibility of discrete fluorescence production and
its rapidity. A fresh SPG solution was prepared prior to
beginning each experiment as recommended by de la Torre
and Surgeon (1976). The solution was of the following
composition : 10.2g sucrose + 4.2g K2P04 dissolved in
100ml distilled water and l.bg glyoxyiic acid crystals
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added. pH was adjusted to 7.4 with 2N NaOH and made up to
a final volume of 150ml with distilled water.
Tissues were excised, the atria and ventricles were
separated and frozen in liquid isopentane cooled with
liquid nitrogen (b.p. isopentane 36°C). The tissue to be
examined was then mounted onto a cryostat chuck using a
few drops of water and frozen to a cryostat temperature
of -20°C. 12Um sections were taken and lifted straight
onto the slides from the cryostat blade, melting onto
the slide by virtue of the temperature difference.
Several slides were then dipped 3 times into the SPG
solution. Excess solution was removed with filter paper
at the edge of the slide and the remainder evaporated
with a cool jet of air. The slides were then heated in an
oven at 80°C for approximately 5 mins. A few drops of
mineral oil at 80°C were then placed on the slide and
mounted with coverslips. Slides were then heated for a
further 2 mins on a hotplate to remove any air bubbles
and to allow the oil to distribute evenly. The slides
were then examined under a fluorescence microscope fitted
wiih a mercury lamp, dark field condenser and a cut-off
filter at approximately 500nm. Photographs were taken on
Ilford FP4 film, ASA 125, developed with Ilford Micro-
phen at 20°C and fixed with Ilford Hypam rapid fixer.
3. Drug Treatments,
Neonatal guinea-pigs were given 50mg/kg 6-OHDA intra-
peritoneally (IP) on days 1,3,5, and 7 after birth, and
21
denervation then persisted indefinitely. Adult animals
were treated with the same dose IP on days 1,2,9 and 14
and sacrificed on day 16. 6-OHDA was made up in 5%
ascorbate. Guinea-pigs were reserpinised by 5mg/kg IP
on each day of the 2 weeks preceding sacrifice.
4.Radioenzymatic determination of plasma and tissue
catecholamines.
Principle: The catecholamines adrenaline (Ad), nor¬
adrenaline (NA), and dopamine (DA) are converted to their
respective 3-0-methylated derivatives using catechol-O-
methyl transferase (COMT) and the radioactive methyl
donor ( H)-methyl-S-adenosylmethionine (SAM). The radio¬
active products of metanephrine (from Ad), normeta-
nephrine (from NA) and methoxytyramine (from DA) are
purified by selective extraction and separated by thin
layer chromatography (TLC). Metanephrine and normeta-
nephrine are finally oxidised to vanillin. The method is
modified from that of da Prada and Zurcher (1976).
Extraction of catechol-O-methvl transferase.
All procedures were carried out on melting ice or at 4°C.
lOOg of rat livers obtained from 10 rats were homogenised
in 400ml 1.19% KC1 and filtered through two layers of
nylon gauze. The homogenate was centrifuged for 10 mins
at 15000 rpm using a refrigerated centrifuge (MSE 18).
The white fluffy floating layer was aspirated and dis¬
carded. The supernatant was then spun for 30mins at
65000 rpm. The pH of the supernatant was then adjusted
to 5.0 using 1M acetic acid and left standing for 20 mins.
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The precipitated proteins were spun down at 24000 rpm
and discarded. Finely-powdered ammonium sulphate (l.61g/
100ml) was then added very slowly under constant stirring.
The precipitated proteins wer spun down after 30 mins at
65000 rpm and discarded. More ammonium sulphate was added
to the spernatant (14.8g/100ml) and left to stand for 15
mins. The precipitate from this stage, containing COMT,
was packed by centrifugation (10 mins at I5000rpm).
The pellet was resuspended in 30 ml ImM NaP04 buffer at
pH 7.0 and dialysed for 15 hours against 51 ImM NaP04
buffer (pH 7.0) containig 77.5mg dithiotreitol (DTT)
with 48 mm circumference dialysis tubing cleaned 3 times
-4
with 10 M EGTA. The precipitated proteins were
sedimented by 10 mins at 15000 rpm and the clear super¬
natant aliquoted into 1ml cups and frozen.
Reagents:
1) 3H-methyl-S-adenosylmethionine, Radiochemical Centre,
Amersham, specific activity lOCi/mmole.
2) Hydrochloric acid;HCl Analar, BDH-10125 37% made up
with double-distilled water (DDW).
3) Perchloric acid;HC104, BDH Analar, 72%, d=1.7,in DDW.
4) Acetic acid; glacial, BDH Analar,d=l.05, in DDW.
5) Sodium hydroxide; NaOH, BDH Analar.
6) Ammonia; ammonia p.a., Merck 25%, d=0.91.
7) Tris buffer; Tris Aristar - 45205, pH 9.6,
8) Borate buffer; Boric acid, Analar, BDH-10058, in
DDW and pH adjusted with 5N NaOH.
9) Dopamine; Kochlight 3283-00 in 0.IN HC1.
10) Adrenaline; L-adrenaline hydrogentartrate, Kochlight
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977.60 in 0.01N HC1.
11) Noradrenaline; L-noradrenaline bitartrate, Kochlight
4351.70 in 0.01N HC1.
12) Magnesium Chloride; 500 mmolar,Merck MgCl2.6H20.
13) Dithiotreitol; A grade, Calbiochem.





15) Carrier solution: 3-methoxytyramine 30.5mg
D,L-metanephrine 29.6mg
D,L-normetanephrine 30.0mg
HC1, 0.01N up to 25ml.
16) TLC tank solvent, per tank: Chloroform 80ml
Ethanol p.a. 15ml
Ethylamine 10ml
17) Scintillation solution B: Butyl-PBD 12.5g
Toluene 2.51
IS) Elution solution for methoxytyramiiie:
Triton X-100 20g
Acetic acid 100ml
Methanol up to 1 1
Procedure:
Plasma_samplesx 1 volume of plasma was deproteinised
using 1 volume of 0.6 HC104, mixed on a vortex mixer and
centrifuged for 5 mins. 2mg NaI04 was added to 1ml of
plasma and the catechols oxidised at 35°C for 10 mins.
lml 0.6N HC104 was then added and the sample mixed and
centrifuged.
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Tissue samples: Tissues were excised and frozen immediately
in liquid nitrogen. The tissue was then powdered by per¬
cussion homogenization and weighed. 10ml per g ice-cold
HCIO^ was then added and centrifuged in a bench ultra-
centrifuge for 10 mins at 15000 rpm. The supernatant was
decanted and the pellet was re-extracted with another equal









HC104 100 - 100 - —
Deproteinised
plasma
- - - 100 100
Oxidised
plasma
- 100 - - -
Standard - - 10-50 50 -
0.01 N HC1 50 50 40-0 - 50
Enzyme mix 100 100 100 100 100
Incubated for 1 hour, continually shaken slowly.






HC104 100 100 - -
Extract - - 100 100
Standard — 50 50 —
0.01N HC1 50 - - 50
Enzyme mix 100 100 100 100
25
Extraction of 3-0-methvlated products from the reaction
mixture:
Tubes were cooled on ice.
200U1 of 3 parts borate buffer to 1 part carrier solution,
freshly-prepared added.
lOOUl sodium tetraphenylborate added.
Catechols were extracred into 10ml diethylether.
Tubes were shaken for 5 mins and centrifuged at 1500 rpm
for 5 mins.
The water phase was frozen on dry ice.
The ether phase was transferred and 0.5ml 0.IN HC1 added.
Tubes were shaken for 5 mins and the water phase frozen on
dry ice.
The ether phase was discarded.
The acid phase containing the methylated products were
washed with 5ml butylacetate and shaken for 5 mins and then
recentrifuged at 1500 rpm for 5 mins.
The water phase was frozen on dry ice and the butyl-
acetate phase discarded.
The acid phase was taken to dryness under high vacuum.
The residue was dissolved in 0.01N HC1.
Separation of the amines:
50U-1 of the purified extract was spotted onto 3 x 20 cm
pre-cut TLC plates with a preadsorbed origin (LK5F,Whatman).
105ml of elution solution was equilibrated in a TLC tank.
12 plates were eluted simultaneously in one tank for approx¬
imately 1 hour. The TLC plates were dried by exposure to a
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stream of cold air. Regions of catecholamines were








The region corresponding to the appearance of methoxy¬
tyramine was scraped carefully with a blade and transferred
with the aid of greaseproof paper to a liquid scintillation
vial. The methoxytyramine was eluted by the addition of
0.5ml 0.IN HC1 and shaken for 20 mins. 10ml of NE260
scintillant was added to each vial, vortex-mixed and
counted.
Elution and oxidation of metanephrine and normetanephrine:
The two regions were scraped separately with a blade and
transferred to liquid scintllation vials VLth the aid of
greaseproof paper. 1ml 2N ammonia was then added and the
vials shaken for 5 mins. 50U1 fresh sodium periodate
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solution was added and the vials shaken for 5 mins. The
oxidation was stopped by the addition of 50U1 glycerol 10%
v/v solution and shaken for 5 mins. 500U1 acetic acid,
ION, was added to readjust the pH. 10ml scintillation
solution B was added. The vials were capped and shaken
vigorously for 20 mins to extract the oxidised products
into the toluene. All vials were then counted for 20 mins.
5. Preparation of guinea-pig cardiac membranes for bind¬
ing studies:
Guinea-pig hearts were excised as quickly as possible
after death. Fat, pericardium and great vessels were
dissected free and the ventricles and atria separated. The
tissues were washed in ice-cold sucrose buffer (0.25M
sucrose, 5mM MgCl2, pH7.4). The tissues were minced finely,
weighed and homogenized in 10 volumes ice-cold sucrose
buffer with 10 strokes of a hand-held Potter-Ehlvehjem glass
homogenizer. The homogenate was filtered through two
layers of nylon gauze then centrifuged at 480g for 10
mins at 4°C. The supernatant was diluted with an equal
volume of 1M KC1 to break down contractile proteins and
left on ice for 10 mins. The supernatant was then re-
centrifuged at 48000g for 10 mins at 4°C. The resulting
membrane pellet was then carefully resuspended in Tris
buffer (50mM Tris, lOmM MgCl2,pH 7.5) and kept at 4°C if
to be used at once or frozen in liquid nitrogen if to be
stored for later use. Protein concentrations were measured
by the method of Lowry et al (1951).
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Preparation of 125I-pindolol:
10U1 13.5mM HC1 containing 20Ug (-)pindolol, 20U1 0.3M
potassium phosphate buffer (pH 7.6), lmCi Na125I (as the
carrier-free compound) and 20U1 aqueous solution of
chloramine T (o.34 mg/ml) were combined in that order in
a polypropylene test tube and allowed to stand at room
temperature for 5 mins. 300U1 aqueous Na2S205 solution
(lmg/ml) was added to stop the reaction. 10U1 IN NaOH was
finally added. The iodinated product was then extracted
4 times with 300H1 portions of ethylacetate containing
0.01% phenol. Phase separation was carried out in a Pasteur
pipette. The 4 washes were combined and spotted onto a
25cm x 40cm strip pf Whatman 3MM paper .and were chrom-
atographed in a descending manner at 4°C with 0.1M
ammonium formiate (pH 8.5) containing 0.01% phenol for 4
hours. The chromatograph was removed from the tank and cut
into 1cm strips while still wet. Each strip was washed in
5ml methanol. The 125I-pindolol forms in a single narrow
peak approximately 7cm from the origin and is separated
well from the remaining unconverted pindolol^ The separate
fractions were counted to detect the purest peaks of radio¬
activity and these fractions were combined. The solution
was dried down under nitrogen flow to give a volume of
lml and stored at -20°C until required.
Binding studies:
Serial dilutions of 125I-iodopindolol (200U1) were
incubated with 300U1 aliquots of guinea-pig atrial or
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ventricular membranes to construct a binding isotherm. The
non-specific binding was determined on all occasions by
the use of a saturating concentration (200UM) of iso-
prenaline. NSB was plotted against concentration of radio¬
ligand to ensure that it was constant. Scatchard analysis
of the radioligand binding (specific bound/free versus
specific bound) gave an estimate of the receptor numbers -
Bmax" ^sP^acemen^ specific 125I-iodopindolol binding
was determined by incubation of a fixed amount of radio¬
ligand with serial dilutions of the competing cold ligand.
The resultant displacement achieved gave an estimate of
the cold ligand's potency. GTP nucleotides are known to
produce an alteration of high affinity binding sites to low
affinity binding sites for ^-adrenoceptors (Kent et al,1979)
and 10~4M Gp(NH)pp was added to a series of displacement
binding studies to determine the proportion of the two
contributing affinity binding states of the (3-adrenoceptor.
Kinetic binding experiments were carried out as above but
at varying incubation times to determine the rate constants
for the ligand-receptor 'on' and 'off' reactions.
All assays contained 5xlO~4M ascorbic acid. Incubations were
carried out at 37°C and were terminated by rapid vacuum
filtration over Whatman GF/C filters and washed with 3 x
4ml Tris buffer. Radioactivity bound to the filters was
measured at 80% efficiency.
Data analysis:
Bmax values were determined by weighted least squares fit
regression analysis. Binding data was fitted by a computer
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modelling programme based upon the law of mass action,
and allowing for multi-compartmental systems of j3-
adrenoceptors,(Minneman et al, 1979; De Lean et al, 1931).
Initial analysis was carried out by hand to check that
there was agreement.
6. Conscious Dog Experiments:
Male foxhounds (22-23 kg) were trained to lie on their
side and remain still throughout a 45 minute test
period. ECG recordings were made with metal plate
electrodes lubricated with saline jelly as a conductant
and strapped to the underside of each limb on a shaved
area. Recordings were made on an Elctromed devices heat
pen recorder. Heart rate, PR and QT intervals were made
at the isoelectric point. Drug infusions smd injections
were made via an intravenous 'butterfly' cannula
inserted into the right radial vein. The (3-blocking
potency of each antagonist employed was assessed by its
ability to shift the log dose - response curve of heart
rate increases to injected isoprenaline to the right.
Bolus injections of isoprenaline were made into a giving
set attached to a sterile saline drip and the heart rate
monitored until the peak response had occurred. Several
doses of the agonist were given at 5 minute intervals.
The antagonist was then injected and after 10 minutes
the curve was repeated. The parallel shift in the log
dose - response curve was taken as an estimate of tne
P-blocking potency of the antagonist. Since all of the
antagonists employed in the study were known to be non-
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selective (3-blockers, it was estimated to be a sufficient
index without a block of vagal tone eg. by atropine.
Antagonist infusions were given over a 30 minute test
period at an infusion rate of lml/min on a Watson -
Marlow infusion pump. ECG recordings were taken at regular
intervals throughout the study .period
f from Lead II.
Alteration of thyroid state:
Dogs were rendered hyperthyroid by oral administration
of 3.3 mg/kg triiodothyronine (T3) in gelatine capsule
form twice daily. Hypothyroid state was produced by oral
administration of lmg/kg carbimazole in gelatine capsules
twice daily. The desired state was considered to have
been achieved when the gross electrophysiological
changes associated with that state were observed in the
ECG traces that were monitored daily. Alterations in
behaviour and physical appearance gave support to the ECG
findings. The agonist and antagonist dose response
curves and infusions were all repeated in each state and
total recovery was permitted between the two treatments.
Blood samples were taken at regular intervals throughout
the treatment cycles in order to monitor plasma T3 and T4
levels which were measured by radioimmunoassay.
Expression of results:
For heart rate responses, increments are expressed as
% increase above resting levels.
Log dose - response curves of the rate responses to
isoprenaline before and after antagonists were used as an
index of their (3-blocking potency. The resultant
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parallel shifts of the log dose - response curves were
used to assess the relative blocking potencies of the
different antagonists. These results were then used to
correct the infused concentrations so as to express all
antagonists in the form of their Dose Ratio (i.e. equating
doses of different antagonists which would achieve an equal
block of response to an agonist). This was in order that
results could be expressed in such a way as to separate
3-blocking effects from any other properties of the drugs
so that any differences between the individual p-blockers
would be more easily apparent.
7.Anaesthetised rats:
Wistar rats of either sex with an average weight of 300g
were anaesthetised with an intraperitoneal injection of
25% urethane (0.7mg/100g). Incisions were made and any
bleeding points coagulated using an Endofrex electro-
surgical unit. The trachea was cannulated and the rat
ventilated with air using a variable stroke Starling
'ideal' pump running at 70 strokes per minute.a jugular
vein was cannulated for the administration of solutions
via a small volume Palmer injection apparatus. Temp¬
erature was held at 37°C by means of a heating pad and
infra red lamps as required. A common carotid artery was
cannulated in order to take 100U1 samples of blood at
5-minute intervals throughout the experiment. Blood gas
tensions were measured on a Blood Micro System connected
to an acid-base analyser (Radiometer, Copenhagen). The
system was calibrated with a high and low concentration
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of gases passed from a calibration cylinder and bubbled
through a humidifier and past the detector electrode
membranes at 37°C. The low concentration gas mixture
was 3% C02 in 97% N2 and the high concentration was
10% C02 in 40% N2 and 50% 02. The relative partial pressures
of the gas mixture were corrected for water vapour content
and atmospheric pressure (AP) by the formula
partial pressure gas X = AP - 49 x % gas X
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ECG records from lead II were recorded with a capacitatively
coupled amplifier passing a band between 50 and 70 Hz.
Results of the (3-blocker infusions in the ventilated and
and unventilated rat were expressed in terms of dose ratios
extrapolated from the previous dog data since it was
found to be impossible to evoke a heart rate response
to isoprenaline in the anaesthetised rat.
8. Expression of results:
Unless otherwise stated, results are expressed either as
absolute changes or as percentage changes from control
values. Where results have been pooled, each value is
an expression of the mean of the pool and standard
deviations are given where appropriate, and number of
observations given. Regression analyses were carried
out by the least squares fit method and 95% confidence
limits for the regression lines are shown if two
regression lines are significantly different from each
other. Student's *t'-test, Wilcoxon rank tests or an
analysis of variance were used to calculate the sig¬
nificance of results, changes being considered sig¬
nificant at the 1% or 5% level.
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9. Drugs used:
The chemical structures and forms of the drugs used
















































CARBIMAZOLE (Nicholas) HO H PROCATEROL(Otsuka)
Ery t hro-DL-1-(7-methylindan-^-yloxyl)-3-isopropylamino -
butan-2-al ICI 118 551 ( ICI )
1 -(5-chloracetylaminobenzfuran-2-yl) -2-isopro pylamino-
ethanol Ro-03 789£ (Roche)
All drugs used in HCl form except t as Na salt.
36
SECTION III : RESULTS
The effects of Q-hydrgxyclpDamine pretreatment on the
catecholamine stores of the guinea-pig heart.
The effects of 6-OHDA pretreatment on the stores of
catecholamines of the guinea-pig heart were examined
by two different experimental means: a) autofluorescence
microscopy and b) radioenzymatic determination.
Autof luorescence_m.i croscopy:
This investigation was carried out according to the
sucrose-phosphate-glyoxylic acid (SPG) method of de la
Torre and Surgeon (1976) because of its simplicity,
sensitivity and stability. The resulting photographs are
shown in Figs. 2 and 3. Figs. 2a) and b) show the alter¬
ation in catecholamine fluorescence brought about by 6-
OHDA pretreatment of guinea-pig atria while Figs 3a) and
b) show the corresponding alteration in guinea-pig
ventricles. It is obvious that there is a significant
gross reduction in fluorescence in the denervated organs.
The strings of fluorescent vesicles seen in the control
photographs were consistently absent from the ohemically-
denervated tissues. It is possible that a small com¬
ponent of the remaining fluorescence is due to a cross-
reactivity with serotonin-containing cells or be due
to residual dopamine-containing stores which may not be
depleted to the same extent as the other catecholamines.
Radioenz£matic_de termination.^
The method used to quantify the catecholamine content
FIGURE 2
Autofluorescence micrographs of atrial catecholamines
observed by the SPG method in the control (a) and






Autofluorescence micrographs of ventricular catecholamines
observed by the SPG method in the control (a) and the 6-
hydroxydopamine - sympathectomized (b) guinea-pig.
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of the control and denervated hearts was a radio-
enzymatic method modified from that of Da Prada and
Zurcher (1976). This method was used to quantify both
cardiac and circulating plasma levels of adrenaline,
noradrenaline and dopamine. The results may be seen
in Table 1. As was expected,,a control cardiac NA:Ad
ratio of approximately 10:1 was observed and this was
not significantly altered in the denervated organ. In
the heart, both Ad and NA were reduced by approximately
97% while the reduction in DA content was not large
but was still significant at approximately 30% reduction.
The plasma levels of catecholamines indicated a higher
proportion of Ad as expected from a basal adrenal
release. Plasma catecholamines proved to be more res¬
istant than cardiac catecholamines to depletion, NA
being reduced by 87% and Ad by 53%, no values being
available for DA. This result may be due to a 'buffering'
effect of catecholamines released from regions more
resistant to depletion by 6-OHDA, possibly related to
the length of the sympathetic postganglionic axon, blood
supply etc such as in the genito-urinary tract or the sex
organs, though, in fact, may be accounted for solely
by elevated release from the adrenals if there was no
significant alteration of release from other * resistant'
organs (de Champlain and van Ameringen, 1973). This is
indeed indicated by the decreased NA:Ad ratio .
THEEFFECTSOF6-HYDROXYDOPAMINEPRETR ATMENTN CARDIACANDIRCULATINGATECHOLAMINELEVELS.
AMINE
CONTROL CARDIAC pg/mgwet weight-tissue
6-OHDA CARDIAC jjg/mgwet weight-tissue
%reduction
CONTROL CIRCULATING ng/ml plasma





























The effects of chemical denervation on responses of
isolated guinea-pig atria to adrenergic stimuli.
6-OHDA pretreated guinea-pigs appeared outwardly normal
and exhibited no overt signs of distress. Guinea-pigs
pretreated with reserpine, however, appeared listless
and lethargic within 24 hours of ther first intra¬
peritoneal injection and this was often accompanied by
impairment of muscular coordination.
Control, atria._
The effects of a series of agonists and antagonists
were examined on both spontaneously-beating and
electrically-driven atria in order to separate the
inotropic and chronotropic effects of the drugs as far
as possible. All drug additions were carried out in
duplicate. Fig 4a shows a typical comparison of the
effects of isoprenaline and salbutamol on the chrono¬
tropic response of right atria. Salbutamol acted to
produce a sub-maximal response when measured against
isoprenaline, evoking a 65% maximum chronotropic and a
55% maximum inotropic response, previously described
as partial agonism (Broadley and Lumley. 1977). Fig 4b
demonstrates a similar comparison of the effects of
NA and isoprenaline (ISO). NA evoked a maximal chrono¬
tropic and inotropic response when compared to ISO
and was of the same order of potency. Fig 5 shows the
very weak positive chronotropic effect of 6-OHDA
itself. The effect was also observed as an inotropic




Log dose - response curves showing the relative
effects of cumulative doses of isoprenaline (x)




Log dose - response curves showing the relation
between cumulative doses of isoprenaline (o)'




-8 -7 -6 -5 -4
Log10 Dose(M)
Log dose - response curves showing the relationship
between the rate responses of the control free-
running guinea-pig atrium to isoprenaline (x) and
to 6-hydroxydopamine (o).
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weak, though dose-dependency was evident, the equi-
potent molar ratio (EMR) for both was approximately 600.
In 6-OHDA - pretreated atria, however, 6-OHDA addition
to the organ bath evoked no response at all. When 6-OHDA
was present in the bathing medium during construction of
a dose - response curve to ISO, it was seen that it
produced no antagonistic effect of the evoked response
at receptor level, see Fig 6. The addition of antag¬
onists produced shifts in the log dose - response curves
of right and left atria to the agonists employed. Fig 7
shows an example of the parallel shift produced in the
log dose - response curve to ISO by the *cardioselective'
antagonist practolol. This p.,-selective antagonist
behaved in a similar manner when used against NA and
salbutamol (Salb) indicating a first - order comp-
etetive antagonism of the positive inotropic and
chronotropic response to an adrenergic stimulus.
Although Salb was shown to consistently produce a sub-
maximal response in control atria, this response was
still susceptible to shifting by antagonists, eg. by
the non-selective irreversible antagonist Ro-03 7894,
but its 'maximum' effect was depressed, see Fig 8.
All values measured are shown in Table J. The order of
potency for practolol (p,-selective) was NA > ISO > Salb;
for Ro-03 7894 (non-selective) the order was ISO > NA >
Salb; for ICI 113 551 ((32-selective) the order was
Salb > ISO > NA, all measurements in the rank differing





-8 -7 -6 -5 -4
Log10 Dose(M)
Log dose - response curves showing the effect of
cumulative doses of isoprenaline (x) on the tension
response of the electrically-driven control guinea-
_5
pig atrium in the absence and presence of 10 M 6-





Log dose - response curves showing the effect of
cumulative doses of isoprenaline (x) on the rate
response of the spontaneously-beating control
guinea-pig atrium and the parallel shift produced
in the presence of 10 M practolol (o).
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-7 -6 -5 -4 -3
Log10 Dose ( M)
Log dose - r«. sponse curves jhowing the sub-
maximal effect of salbutamol alien compared to
isoprenaline (100,j) on tension responses of the
I
electrically-driven control left guinea-pig atrium
(x) and the shift produced by the addition of




£omparison_of control and denervated^a^ria.^.
Combinations of experiments coordinating selective and
non-selective agonists and antagonists were carried out
in both control and denervated atria. It is well-
documented that a selective supersensitivity of both
chronotropic and inotropic responses occurs following
reserpine - pretreatment of atria (Broadley and Lumley,
1977). This observation was borne out in the present
study. However, no such supersensitivity was observed
in the case of chemical denervation by 6-OHDA. The
EC50 values are given in Table 2. Responses to Salb were
also enhanced after reserpine - pretreatment but a
supersensitivity to NA was not demonstrated, indeed a
decreased sensitivity was noted. On the other hand,
responses to ISO and NA were unchanged following 6-OHDA
pretreatment. However, responses to Salb could not be
evoked after 6-OHDA. Even at doses 1000 times those
producing its maximal response in control atria, no
response at all was observed. In all cases, adult and
newborn - treated atria gave identical results. In all
cases, agonists displayed a rate selectivity and this
may also be seen in Table 2 from their EC5q values.
This rate selectivity and order of potency are main¬
tained in both control and denervated atria, ISO >
NA > Salb.
While no response was obtained to Salb after 6-OHDA,
it in fact proved to be an antagonist of responses to
ISO and NA. It produced a parallel shift in the log








































*Significantlydifferentfromcontrol,P>0.05(Man -Whitneyra ktes ) ECvaluesforthein tropicandchro otropicresp ns s 5© ofcontrol,reserpinizedand6-OHDA-pret eatedguinea- pigatriatonon-selective,|3-selectivd{ 2 selectiveagonist.
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against the action of ISO, the Kg values being
listed along with those of the true antagonists in
Table J.
The effects of tyramine were then tested in control
and denervated atria to examine the releasable pool of
catecholamines in response to an indirectly - acting
sympathomimetic amine. Tyramine produced a weak, dose-
related chronotropic and inotropic effect in control
atria but this action was not seen in reserpinised or
6-OHDA pretreated atria, indicating an absence of the
releasable pool. The effects of catecholamine depletion
by reserpine on the K a values of a p., -selective
(practolol) and a non-selective (Ro-03 7894) adreno¬
ceptor antagonist are depicted in Table 3. The affinity
constants of the two types of blocker were unchanged
when measured against Salb. The values for the non¬
selective antagonist were decreased for both chrono¬
tropic and inotropic responses when measured against
the non-selective and the p.,-selective agonist. The
Kg values for the 'cardioselective' p,-blocker practolol
were affected in the opposite direction and were
increased in both cases.
Table 4 shows the effects of 6-OHDA - induced denervation
on the Ka values.of a non-selective (Ro-03 7894), a p,-
selective (practolol) and a p2-selective antagonist
(ICI 118 551) against a selective and a non-selective
agonist. The values for the p2-selective and the non-
selectiveantagonists remained unchanged but the K
3.
TA B L E 3
The effects of reserpine - pretreatment on the
Ka values of a ^-selective and a non-selective
adrenoceptor antagonist.
ANTAGONIST AGONIST































































value for practolol was increased for both chronotropic
and inotropic responses, both adult and neonatal tissues
maintaining their identical responses.
The effects of 6-hydroxydopami'ne pretreatment on the
responses of guinea-pig trachea to adrenergic stimuli.
The effect of a series of agonists and antagonists on
the relaxation responses of guinea-pig tracheal strips
that had developed spontaneous tone were examined. All
drug additions were carried out in duplicate.
Both non-selective ISO and (32-selective Salb proved to
be full agonists in the trachea. Fig 9a shows an example
of the parallel shift to the right of the log dose -
response curve obtained to ISO produced by the addition
of the p2-selective antagonist butoxamine. Fig 9b shows
a similar case for the shift of the full agonistic
effect of Salb by (32-selective ICI 118 551, also being
of an exactly parallel nature. A summary of the EMR
and K values for all of the drugs employed are shown
3.
in Table K.
In control tracheae, the (32 -selective agonist procaterol
was more potent than Salb, the EMR of procaterol (PROC)
measured against a value of 1 for ISO being 1.93,
that of Salb being 3.01.
6-OHDA pretreatment had no effect on the ability of
tracheal ^iral strips to develop spontaneous tone.
The order of potency of the three agonists used was




Log dose - response curve produced by the addition
of cumulative doses of isoprenaline (x) in the control
guinea-pig trachea and its parallel shift in the





Log dose - response curve showing the effect
of cumulative doses of salbutamol on tension
responses of the control guinea-pig trachea (x)
and the parallel shift produced by the addition
of 10"6M ICI 118 551 (o).
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Salb.
The Ka values for the series of antagonists used are
listed in Table 5. The figures yield the rank potency
orders of ICI 118 551 (p2-selective) > ^propranolol
(non-selective) > butoxamine (p2-selective) > practolol
(p,-selective). The rank order of potency was identical
when measured against Salb, indicating that both
agonists are acting of the same receptor pool. The
rank order of potency was also maintained when measured
against both agonists in the 6-OIIDA - pretreated trachea.
In the cases of measuremants being made for PROC,
the potencies were also in the same order. Table 5
lists the changes in Ka values of the antagonist series
after S-OHDA treatment. In all agonist cases, the (3^
selective antagonist practolol and non-selective prop¬
ranolol K0 measurements significantly increased whereas
the values for both of the (32-selective antagonists
significantly decreased. Levels of significance are
indicated in the table.
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TABLE 5
ANTAGONIST AGONIST CONTROL 60HDA
PRACT0L0L
(p,-selective)





ISOPRENALINE 9.56xl07 6.14xl08 Y
SALBUTAMOL 4.88xl08 6.60xl08 w
BUTOXAMINE
((32-selective)
ISOPRENALINE 6-OOxlO5 2.03xl05 Y
SALBUTAMOL 2.48xl06 1.49xl06 w




SALBUTAMOL 4.96xlO? l.iixio7 y
PROCATEROL 6.30xl06 2.05xl06 y
Effects of 6-OHDA pretreatment on the K values of
3.
a series of selective and non-selective antagonists
and agonists in the guinea-pig trachea.
■y denotes significant difference from control at 1%,
oj denotes a 5% level of significance.
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Binding Studies.
A series of binding studies on guinea-pig cardiac
microsomal membranes were carried out to test for an
agreement of data with the isolated atria experiments.
For each experiment, a homogenate of* 20 guinea-pig
hearts was required, separated into atria and ventricles
or combined. Since in the isolated organ work the adult-
and neonatal-treated guinea-pigs behaved in an identical
manner, adults were used for the binding studies since
they provide a much greater weight of cardiac tissue
per animal.
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The radioligand used for the studies was (-) *" I-iodo-
pindolol (IPin) and it was first tested to see if its
binding properties conformed to those required. It
was confirmed that the non-specific binding (NSB) rose
linearly with total radioactivity present (see Fig 10),
this linear relationship making its elimination by
simple subtraction possible. NSB was linear in all
control and 6-OHDA cases , any discrepancy in their
respective results therefore not being due to a
'masking' of specific binding by alterations in NSB
sites, A binding isotherm to IPin was pi-oduced, see
Fig 11a. The curves were constructed in the presence of
a 'saturating' concentration of 200pM (+) isoprenaline
to take up the non-specific and non-stereospecific
binding sites. The figure shows the saturable,
concentration-dependent nature of the specific binding
of IPin. Specific binding increased linearly with
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FIGURE 10
The relationship of NSB as assessed by the
presence of 200pM (+) isoprenaline and the




Saturation curve of IPin binding
b)







Bmax = 111 ±9-2
KD=286pM
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membrane concentration over the protein range employed
in the study (50 - 200 Ug protein per assay). Since
IPin is a non-selective adrenoceptor antagonist, as
expected it produced a monophasic Scatchard plot,
see Fig lib. A comparison of control and 6-OHDA
combined atria and ventricle.-membranes yielded Scatchard
plots which showed up the gross differences in binding
site density produced by chemical denervation. The
density of ligand binding sites (Bmax) was approximately
doubled in the denervated organs. Control hearts had a
Bmax value of 60+6.5 fmol/mg protein while the value
for the denervated tissues was 111 +9.2 fmol/mg protein.
- and g.2-adrenoceptor subgopulations.
The existence of two or more subpopulations of j3-
adrenoceptors and their relative densities was examined
by means of inhibition of specific IPin binding by a
series of selective and non-selective agonists and
antagonists.
When isoprenaline or pindolol was used as the cold
displacing ligand, the Hoffstee plots obtained were
linear. This was as expected since neither compound
differentiates in its binding to p, of p2~adrenoceptorsf
see Fig 12, and this result could be explained by the
presence of one or more receptor subtypes.
When the competing cold ligand was a (3.,-selective
agonist NA or antagonist practolol, a different type of
plot emerged. The plot was now biphasic in both cases,
the high affinity component (presumably (3,) being
considerably larger than the low affinity (p2) component.
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FIGURE 12
BOUND / [ DISPLACER ]
Inhibition of specific IPin binding in guinea-pig
atrial membranes by 31-selective drugs noradrenaline
and practolol, 32-selec'kive isoetharine and ICI 118
and non-selective isoprenaline and pindolol.
• - control, o - 60HDA-denervated membranes.
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When the (32-selective agonist isoetharine or the |32-
selective antagonist ICI 116 551 was used, the plot
also became biphasic, though in this case it was the
high affinity ((32) component which was the smaller and
the low affinity (B^ which was the larger t see Fig 12.
In both control and denervated atria and ventricles,
the order of potency for the agonists used was ISO >
NA > isoetharine. This indicates that the major
component of the adrenoceptor pool in all cases is p.,
and it further confirms the potency order of agonists
as recorded from the isolated atria work mentioned
earlier.
Table 6 lists the percentages of p,- and ^-adreno¬
ceptors distributed in atria and ventricles of control
and denervated guinea-pig hearts. The values are
calculated from studies of inhibition of specific IPin
binding. It may be seen that the p., population'is
predominant in both atria and ventricles but that the
Pi population is consistently higher in the ventricles.
Denervation by 6-OHDA produced an increase in the atrial
P1:P2 ratio from 69.9:30.1 to 81.0:19.0 and in the
ventricles from 75.7:24.2 to 85.3:14.7. The data was
assessed by computer modelling analysis in all cases.
Kinetic studi.es._
Kinetic experiments were carried out in order to
determine the dissociation rate constant values (KD)
for the drugs when being used to displace equilibrated
IPin binding on a time scale. The results obtained





























































%DistributionoffSl-and(32-adrenocept rsintriadventricl sofco trol and6-OHDA-denervatedguine -pigs.Numberofbs rvationsshownibrackets. Resultscalc la edbycomputermodellingfr mdispla em ntfsp cificinding.
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were best fitted by a one- or two-compartmental model.
Non-selective ISO yielded a uniphasic displacement
curve with time while selective agonists and antagonists
produced biphasic displacements. values were not
significantly different for atria and ventricles, or
between control and denervated tissues showing that the
binding site affinities were unaltered by denervation.
The rate constant fealues for p, and p2 populations
were as follows: NA 1.3,8.9; isoetharine 3.29,0.68;
ICI 118 551 0.81, 0.31; practolol 2.5, 5-4.6; ISO 1.21.
It seems that the rates of displacement of specific
binding by selective and non-selective agonists or
antagonists remains unaltered by chemical denervation.
Hi£h^and^low^affi.ni.tx states^.
It has previously been shown (Kent et al,1979) that
guanine nucleotides such as guanine triphosphate (GTP)
which play a role in the adrenoceptor-mediated acti¬
vation of the adenylate cyclase enzyme, mediate a
transition of high affinity binding states of the
adrenoceptor to low affinity binding states. A number
of experiments were carried out to examine the ability
of the nucleotide Gpp(NH)p (a stable non-hydrolysable
form of GTP) to mediate this transition in the den¬
ervated guinea-pig cardiac membranes, see Fig 13.
The Fig shows the alterations in displacement of
specific IPin binding by and (32-selective agonists
-4
in the presence of 10 M GTP nucleotide in the control
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FIGURE 13
- Loq„^ [ isoethcrine]10
The effects of 10" M GTP on the inhibition
of specific IPin binding by Noradrenaline (a)
and Isoetharine (b) in guinea-pig ventricular
membranes.
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and denervated ventricular membranes. It may be seen
that in both cases of control ventricles, the dis¬
placements of specific binding are shifted to the left
on a -log^Q scale indicating that the agonist was less
potent in the presence of GTP, i.e. that the binding
affinity was decreased. In control and 6-OHDA ventricles,
the EC,_„ values for isoetharine and NA were not sig-
5U
nificantly altered (1.8 x 10"^ and 2.2 x 10~® res¬
pectively) .
In denervated membranes, the shift in the curves was
of a similar order and was still observed indicating
that the interconversion of high and low affinity
states of the adrenoceptor still exists, and presumably
it is in the same relationship as in control tissues.
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The Effects of Sotalol, Propranolol and Nadolol on thfe
Electrocardiographs of Conscious Dogs.
The Jl-blocking_effects^of the antagonists used^
Figs 14a-c show the effects of sotalol, propranolol
and nadolol on heart rate responses forinjected ISO.
In all cases the log dose - response curves were shifted
to the right in a parallel manner, indicating a com¬
petitive mode of action. Doses of the antagonists
administered were adjusted so as to produce the same
order of antagonism, since a dose of nadolol similar
to that of sotalol was so potent as to cause a dep¬
ression of maximum as well as a shift to the right, and
we wished to examine the competitive range of antagonism
only. The comparative dose ratios (DR) produced by the
three (3-blockers were then used to plot their effects
on the ECG parameters, the DR value of propranolol
being corrected by a factor of 8.65 and nadolol by 134
in order to express their results in terms of (3-blocking
,potency alone. This method of data plotting was in order
to compare their p-blocking effects with their other
actions. The DR values obtained were not significantly
altered by either T3 or carbimazole treatments, nor
was any change in the response to injected ISO seen.
Table 7 shows the basal control levels of the measured
ECG variables. There was no significant difference
between the control basal levels for any of the three
blockers in each condition. No significant alterations

































Log dose (ng/kg )
Heart rate responses to injected isoprenaline in the
conscious dog before and after the administration of
1.25 mg/kg sotalol. Results shown are from duplicate
estimates in each of 4 dogs.
x - isoprenaline alone o - isoprenaline in the presence























QC Shift =1-58 log units
DR = 38
Log dosa ing/kg )10
Heart rate responses to injected isoprenaline in the
conscious dog before and after the administration of
0.5 mg/kg propranolol. Results shown are frem duplicate
estimates in each of 4 dogs.
x - isoprenaline alone • - isoprenaline in the presence






























( 3 • 64 jj g / kg )
ine
Shift = 1-03 log units
DR =10•7
Log dose ( ng/kg )
10
Heart rate responses to injected isoprenaline in the
conscious dog before and after the administration of
3.64ug/kg nadolol. Results shown are from duplicate
estimates in each of 4 dogs.
x - isoprenaline alone • - isoprenaline in the
presence of 3.64 Ug/kg nadolol.


































































carbimazole treatment. In the T3-treated group,
however, heart rate (HR), QT interval and QT/RR ratio
were all significantly greater than in the control group
at the levels of significance indicated. No significant
alteration in the PR interval was observed.
Table 8 lists the properties of the p-blockers employed
in the present study.
The effects of^Tj. or^Cjirbimazoie_treatment_on
circulating_T3. and Thieve Is.
Fig 15 shows the plasma levels of T3 and T4 in the
control, T3- and carbimazole-treated dogs. Levels
of plasma hormones were detected by radioimmunoassay.
Plasma T4 was depressed by both treatments, but the
effect was not significant. However, T3 levels were
significantly increased during T3 administration as
expected.
The effects of_sotalol_infusion on^ECGparameters.
The effects of sotalol infusion on the ECG variables
in control, carbimazole- and T3-pretreated dogs are
shown in Tables A(i) - (iv), B(i) - (iv) and C(i) - (iv)
respectively.
Carbimazole treatment produced lethargy in the dogs,
accompanied by swelling of the paws and weight increase.
T3 treatment caused a significant increase in the resting
HR, with restlessness, weight loss and a decrease in
body temperature.
Fig 16a shows the effects of sotalol infusion (final










Control Carbimazole- T3 - treated
treated
Plasma levels of T4 and T3 in control, carbimazole-
treated and tri-iodothyronine (T3) - treated dogs.
Levels were detected by radio-immunoassay.
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FIGURE 16












Sraight lines represent least squares regression fit.
Curved lines represent 95% confidence limits of the
regression analyses and are shown if significantly
different from control.
Effect of sotalol Infusion on QT interval
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and T3-pretreated dogs. The PR interval increased in
a dose-dependent manner with increasing sotalol
concentration and, although the effect was small, it
was significant. As may be seen from the confidence
limits of the least squares regression analysis, the
effect on the increased PR interval was significantly
depressed by T3 treatment. The effect was unaltered by
carbimazole.
In Fig 16b the effects of sotalol infusion on QT
interval are shown. In all cases there was a highly sig¬
nificant dose-dependent increase in QT interval with
sotalol infusion. This effect was significantly dep¬
ressed by carbimazole and was significantly enhanced by
T3 treatment.
The effects of sotalol on HR are shown in Fig 17a.
Although there was a consistent decrease in HR with
increasing dose of sotalol, the trend was not a sig¬
nificant one. In the T3 treatment, however, the
decreased HR with increased dose became significant at
the 5% level.
Fig 17b shows the effects of sotalol infusion on the
QT/RR ratio in the three conditions. This ratio was
used as an index of 'refractoriness' of the heart. The
control and carbimazole states were not significantly
different from each other but in T3 treatment the ratio
was significantly greater. Although the resting QT/RR
ratio was higher in the T3 group, the increments with
increasing dose of sotalol remained and, indeed,
control and T3 results were parallel.
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FIGURE 17
Effect of sototol infusion on heart rote
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The effects of_progranolol_infusion on_ECG_parameters. _
The effects of propranolol infusion on all ECG parameters
in control, carbimazole- and T3-pretreated dogs are
shown in Tables D(i) - (iv), E( i) - (iv) and F(i) - (iv)
respectively.
Fig 18a shows the effects of propranolol infusion
(final dose 2mg/kg) on PR interval. The effects were
significantly depressed by both carbimazole and T3
treatments, both results having significant slopes at
the 5% level of significance.
The effects of propranolol on QT interval are shown in
Fig 18b. The slopes were all significantly different
from zero at 5% level but were not significantly
different from each other.
The HR effects are shown in Fig 19a. The dose-dependent
decrease in HR observed in the control state was
unchanged by carbimazole but was significantly depressed
by T3 treatment and the responses were shifted in a
parallel manner to the right.
Propranolol infusion effects on QT/RR ratio are graphed
in Fig 19b. In all cases there was a significant
decrease in the ratio which was in the opposite direction
from the sotalol results. Carbimazole and T3 both failed
to alter the results and all of the confidence limits
overlap.
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filed of propranolol infusion on heart rale














The effects of_nadolol_infusjion on_E^G_p^ramete.
The effects of nadolol infusion (final dose 5mg/kg) are
listed in Tables G( i) and (ii), H(i) and (ii) and l(i)
and (ii) for control, carbimazole- and T3-treated dogs
respectively. The dose of nadolol given at the end of
the infusion was the same as that for sotalol but, as
was seen in Fig 14a, the (3-blocking potency of nadolol
is far greater then that of sotalol or propranolol and
therefore the DR produced by nadolol in that concentration
is 134 times greater than sotalol. Even at this range,
however, nadolol had no significant effect on any of the
parameters measured and so the data is not included
in graph form.
Figs 20 and 21 show the combined data for sotalol and
propranolol in control and T3 states to demonstrate the
selectivity of the two antagonists for the ECG variables.
It can be seen that propranolol exhibits a markedly
greater effect on PR interval (20a) while sotalol
displays a selectivity for the QT interval (20b).
Sotalol was markedly more effective in lowering HR
than propranolol (21a) and this effect was enhanced by
the T3 treatment while the effects of propranolol in
lowering HR were reduced. The comparison of the two
antagonist infusions on QT/RR ratio shown in fig 21b
show that they shift the ratio in opposite directions,
sotalol increasing and propranolol decreasing the ratio,
the sotalol results were parallel, the propranolol
slopes not significantly altered.
o <±
FIGURE 20
^00 ~ lOOO IOCXX)
Dose Ratio
Effect of aotalol or propranolol Infusion on PR Interval
/3
1 - control aotalol
2 - T3 aotalol
3 - control propranolol
4 - T3 propranolol
Effect of aotalol or propranolol Infusion on QT Interval
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FIGURE 21
fc'ftecl o( solalol or propronolol infusion on heart rote




























Effect of sotalol or propranolol infusion on O-T/R-R ratio
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B-Blocker toxicity in the anaesthetised rat.
The (3-blockers tested on conscious dogs in the previous
section were then used in a series of experiments on
anaesthetised rats. We examined the relative toxicity of
the three antagonists sotalol, propranolol and nadolol
in ventilated and unventilated rats.
Table 9 shows the numbers of cases of (3-blocker poison¬
ings reported to the National Poisonings Information
Service during a 1-year period. It is interesting to
note that there appears to be no correlation between
the number of cases reported for each blocker and its
share of the sales market. The most * toxic' blocker
appears to be propranolol with far more poisoning
cases reported than expected from its relative use.
Other blockers with significant usage have only a few
reported poisoning cases.
The effect of sotalol or propranolol on PR interval
was unaffected by ventilation. Nadolol produced no
effect on PR. The effects of all three drugs on the QT
intervalare shown in Fig 22. The effects were all
unaltered by ventilation, the effects of nadolol being
extrem ly weak. As expected, sotalol was the most potent
antagonist in terms of increasing QT interval due to its
Class III antidysrhythmic properties.
Fig 23 shows the relationship between the toxicities of
the (3-blockers when infused into ventilated and un¬
ventilated rats. In all cases, rats that were ventilated
survived a much longer time and a far higher dose of
87
TABLE 9
P-blocker overdosage (1980 - 1981)
MARKET SHARE NO. REPORTS





































Relationship between the toxicities of (3-blockers
in the ventilated and unventilated anaesthetised
rat. Numbers of experiments are shown in brackets.
»
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blocker was withstood before death occurred. However,
due to the very different blocking potencies of the
three drugs, the results have also been expressed in
terms of Dose Ratio (DR), see Fig 24. The actual DR
values used in the histogram nabe been extrapolated
from the conscious dog data listed previously. This is
because rats failed to respond to injected ISO in terms
of increased HR and it was therefore impossible to
produce a log dose - response curve with which to assess
the DR values of the drugs directly in the rat. From
Fig 24 it is apparent that nadolol, due to its far higher
DR. is tolerated much better than the other two com¬
pounds and that the lethal dose is much greater in
ventilated animals. The mean dose at death produced
the rank potency order of propranolol > nadolol >
sotalol in both ventilated and unventilated rats. The
ratio of lethal doses in ventilated : unventilated rats
was 1.5 for propranolol, 6 for nadolol and 4 for
sotalol. However, when the data was recalculated fpr
DR values as shown, the potency order emerged differently
being propranolol >/ sotalol >> nadolol; propranolol
and sotalol being approximately 130 times as toxic as
nadolol.
The gross effects on ECG were then examined. Fig 25
shows sections of ECG taken during sotalol infusion in
a) unventilated and b) ventilated rats. In unventilated
animals, the average time of death was 28 mins. It
can be seen that a gradual slowing of HR occurred with
91


















p-BLOCKER DOSE AT DEATH
(5)
NADOLOL SOTALOL
I Unventilated □ Ventilated
Relationship between lethal doses of (3-blockers
in ventilated and unventilated anaesthetised rats
expressed in terms of dose ratios - figures being
extrapolated from previous dog experiments.
Numbers of experiments are shown in brackets.
a)ECG-SOTALOLUNVENTILATED RATEOFDRUGINFUSION=3-6mg/min DEADAT28min& CONTRObpCOo=28mmHg;p02=90mmHg;HR=307bt/min y 5MIN-pC02=28mmHg;p02=97mmHg;HR=22lbt/min \ 4.V_—-t 1QMIN-pC02=37mmHg;p02=75mmHg;HR=185bt/min 75MIN —iN-_pC02=71mmHg;p02=24mmHg,HR=108bt/min
-f-
b)£CG-SOTALOLVFNTII.AT'ED RATEOFD UGINFUSION=3-6mg/min 75MIN-pC02=10mmHg;p02=152mmHg;HR=142bt/min 115MIN-pC02=10mmHg;p02=150mmHg;HR=77bt/minDEADATI38mins. CONTROLpC02=2ImmHg;p02=125mmHg;HR=26lbt/min 10MIN-pC02=16mmHg;p02=14ImmHg;HR=212bt/min
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increasing dose. In control rats and also those
receiving 0-blocker infusions, we frequently saw a
transient switch into a junctional or nodal rhythm
recognised by inversion of the P waves which always
reverted back to sinus rhythm. All animals appeared to
be in sinus rhythm prior to the onset of cardiac death.
With nadolol (see Fig 26) the same pattern of gradual
slowing with increasing dose was seen. The average time
of death in the unventilated rat a) was 8 mins and in
the ventilated rat b) was 85 mins. Again, sinus rhythm
was followed right up until the time of death. In the
case of propranolol, however, (Fig 27) a different
trend was observed. An atrio-ventricular block gradually
developed throughout the infusion until a full 2:1
conduction block was present a). This was repeated in
the ventilated animal (b) though there was still a
prolongation of survival time.
Since it was shown in Fig 23 that the DR values of the
P-blockers at death were very different, it seems that
death in these cases of toxicity are not due simply to
p-blockade or the DR values would be expected to be more
similar. Therefore the blood gas tensions were studied
throughout the infusions.
The increased survival time in ventilated rats in all
three cases and the fact that pC02 values increased
dramatically while p02 values decreased prior to death
in all unventilated but not ventilated rats suggests
that death due to |3-blocker overdose is caused at least
in part by respiratory depression in the unventilated rat.
a)FCG-NADOLOLUNVENTILATED RATEOFDRUGINFUSION=3-6mg/min. DEADAT10minutes. CONTROL5PC02=37mmHg;p02=91mmHg;HR=38bt/ in 2-MIN.-pC02=35mmHg;02=85 mHg;HR=320bt/min AMIN.-PC02=68mmHg;p02=37mmHg;HR=266bt/min 7MIN.-PC02=94mmHg;p02=35 mHg;HR=64bt/min





25MIN-pC02=16mmHg;p02=11ImmHg;HR=l56bt/ Jfv—-min 80MIN-pC02=13mmHg;p 2=112mmHg;HR=85bt/min f^—
a)EHQ-PROPRANOLOl.UNVEN'THATPC) RATEOFDRUGINFUSION=1-2mg/min DEADAT10min.3sgcs CONTROL-Pc02=36mmHg;p=8I mHg;HR=38lbt/ in MJfUiUvJv4u.uVAJfUj 5MIN,-pC02=35mmHg;p02=36mmHg 6MIN-pC02=35mmHg;p02=34mmHg;HR=13lbt/min 9MIN-PU02=45mmHg;p02=llmmHg
b)ECG-PROPRANOLOLV NTIL TED RATEOFDRUGINFUSION=1-2mg/min DEADAT13mins. CONTROL-pCOo=25mmHg;p02=40mmHg;HR=387bt/ in 9MINPC0*=9mmHg»P0245mmHg;HR=176bt/min 12MIN-PC02=9mmHg;p0242 mHg -aw_,,,.
96
Whether the respiratory depressing effect of the three
antagonists is a central or peripheral effect would
apparently depend on their relative pharmacokinetic
properties, see Table 10. If the effects were central,
it would be predicted that propranolol would be the
most toxic followed by nadolol and then sotalol, since
propranolol has the highest partition coefficient, all
having approximately equal pKa values. However, although
propranolol indeed proved to be the most toxic, nadolol
was the least so and therefore the expected order was
not maintained. A peripheral effect on respiration or
a central effect not dependent on crossing the blood -
brain barrier therefore seems a likely explanation.




























SECTION IV : DISCUSSION
The effects of 6-hydroxydopamine pretreatment on guinea-
pig cardiac catecholamine stores.
The sympathectomy of guinea-pigs by 6-OHDA was confirmed
by autofluorescence microscopy and radioenzymatic
studies. The former yielded the information that there
was a gross reduction in catecholamine fluorescence
following 6-OHDA treatment in both atria and ventricles.
The disappearance of strings of fluorescent vesicles in
the denervated tissues confirms the degenerative effects
of 6-OHDA on the noradrenergic nerve terminals reported
by Thoenen (1972). The small amount of remaining flu¬
orescence may be due to the small percentage of residual
catecholamines or may reflect a cross-reaction with
5HT-containing granules which may have been masked in
the control tissues by the dense specific fluorescence
of the catecholamine-containing granules and vesicles.
This would agree with Mueller et al (1969) who found
that following large doses of 6-OHDA the specific
fluorescence of noradrenergic and dopaminergic terminals
disappeared whereas the fluorescence of 5HT terminals
remained unaffected (confirmed by Malmfors and Sachs,
1968). However, the residual fluorescence is small and
the SPG method was chosen because of its cross-over
reactions are not as obvious as for the more popular
method of Falck et al (1962) for catecholamine visual¬
isation. The significant decrease in specific fluorescence
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was confirmed by the radioenzymatic estimations of
cardiac adrenaline (Ad), noradrenaline (NA) and dopamine
(DA). The massive 97% reduction in Ad and NA content
was considered to be evidence of cardiac sympathectomy.
The approximate 10 : 1 ratio of NA : Ad observed in both
control and denervated hearts indicates that the residual
amines are of cardiac origin. The resistance of DA stores,
seen by only a 30% reduction, confirms to some extent the
findings of Kimata (1965) who found that bilateral
cervical sympathectomy of the dog reduced cardiac NA
markedly with no concomitant change in DA concentration.
Even though we found DA content to be reduced by 1/3,
it appears that DA may continue to be synthesised in
cardiac muscle following denervation. The plasma catechol¬
amines were not reduced to the same extent as cardiac
catecholamines : NA was reduced by 87% and Ad by 53%,
no data being available for DA. Since the adrenals are
said to be completely resistant to sympathectomy with
the chromaffin cells remaining intact (Mueller et
al, 1969), this could be purely a result of adrenal
compensation. They found that 6-OHDA treatment sufficient
to almost totally destroy cardiac nerve terminals of the
rat left those of the adrenal medulla intact. Con¬
comitantly, tyrosine hydroxylase activity (the rate-
determining step of NA synthesis) disappeared from the
heart but greatly increased in the adrenal medulla
indicating a compensatory machanism via trans-synaptic
induction of the tyrosine hydroxylase enzyme was in
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operation. Since this increased enzyme activity was also
noted by Johnnson et al (1976) in rats depleted by
guanethidine, it is likely that the same compensatory
machanism occurs here. It was proposed that the increased
tyrosine hydroxylase activity is mediated by an increased
activity of the preganglionic nerves of the adrenals
(Dahlstr6*m and HSggendal, 1973) which, as described
previously, are unaffected by 6-OHDA pretreatment.
The effects of chemical denervation on the responses
of guinea-pig atria to adrenergic stimuli.
Denervation by 6-OHDA is now accepted as affecting all
levels of the cardiac conduction system. In 1982, Godin
et al found that chemical sympathectomy of dogs with a
single injection of 50mg/kg 6-OHDA caused the spontaneous
cardiac cycle length to rise from 370 - 16 msec in
controls to 514 - 15 msec in depleted dogs. This was not
supported in our study at the same dose in guinea-pigs
and no such alteration in heart rate (HR) was observed
in the spontaneously-beating isolated atria, though the
guinea-pigs were probably more efficiently denervated
after a course of 6-OHDA injections. The results of
Godin et al could perhaps be due to the initial uptake
of 6-OHDA displacing the endogenous neurotransmitter. All
studies were carried out here in the presence of phenoxy-
benzamine and metanephrine to block a-adrenoceptor
stimulation and extra-neuronal uptake to remove any
complications of these affecting ^-adrenoceptor responses.
Langer and Trendelenberg (1969) found that propranolol
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was less effective in tissues against L-NA than L-iso-
prenaline (ISO) but that the antagonism was equal if
uptake mechanisms were blocked. Also, as Furchgott (1972)
stated, all secondary processes influencing the drug
concentration at the receptor must be accounted for.
In control atria, both ISO and NA were found to produce
dose-dependent chrono- and inotropic responses in right
and left atria respectively and both produced the same
rra ximum response. Salbutamol (Salb) on the other hand
consistently failed to produce a maximum response when
measured against that of ISO and NA, evoking a 55%
inotropic and a 65% chronotropic response. These sub-
maximal responses to Salb are in agreement with previous
reports (Brittain et al, 1970; Farmer et al, 1970;
Hughson and Ledsome, 1975) though absolute results did
vary, the latter authors finding a 65% inotropic and a
69% chronotropic response. All groups, however, agreed
that the failure of Salb to attain a maximum response
permitted its classification as a 'partial agonist* at
the |3-adrenoceptor according to the criteria of
Stephenson (1956). When 6-OHDA itself was tested in vitro
it was found to be a very weak agonist for both chrono-
and inotropic effects, but responses were dose-dependent.
This very weak agonistic property (EMR = 600) would
explain the observations of Thoenen and Tranzer (1968)
3
with H-6-0HDA that in the cat spleen it may be released
as a false transmitter. It may be seen from Fig 6 though,
that 6-OHDA produced no antagonism of response to ISO
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when incubated in vitro with the atria. This indicates
that it does not act directly at the (3-adrenoceptor
level to produce its weak positive ino- and chronotropic
effects otherwise it would reduce responses to ISO by
P-receptor occupation. This may therefore be further
evidence for its indirect actions. In the 6-OHDA depleted
atria, different results were obtained. 6-OHDA addition
failed to evoke any response whatever supporting the
findings of Laverty et al (1965), Heusler (1971) and
Kuchii and Shibata (1972). It would therefore appear that
6-OHDA acts in control guinea-pig atria as an indirectly-
acting sympathomimetic amine, producing tissue responses
by displacement of catecholamines from the intact
neurones, hence being unable to produce effects in the
denervated tissues. This difference in activity in control
and denervated atria was confirmed by our findings with
tyramine. It also produced a weak positive chrono- and
inotropic response in a dose-dependent manner in control
atria but failed entirely to do so in depleted atria.
This similarity of results further indicates an indirect
nature of 6-OHDA action. The absence of response to
tyramine in the denervated atria also lends evidence for
near-total catecholamine depletion since Crout et al (1962)
found that a 50% depletion of guinea-pig cardiac NA had
no effect on responses to tyramine. It was only when
cardiac NA was reduced by as much as 70% that a 50%
reduction in responses to tyramine were observed. Since
they found that NA pretreatment restored responses to
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as much as 70% without affecting cardiac NA content, they
proposed a small refillable compartment (supported by
Trendelenberg and Pfeffer,1964) but could, however, be
due to NA binding to non-receptor sites. The fact that
we found total abolition of responses-to tyramine
indicates successful depletion by the above criteria and
we have either a total depletion of catecholamine stores
or no uptake mechanism for 6-OHDA and tyramine or a com¬
bination of the two. In denervated atria, ISO and NA
still acted as full agonists, ISO being more potent for
both chrono- and inotropic effects (EMR values of 1.07
and 3.26 respectively), the values not being significantly
altered by denervation. However, Salb now produced no
response whatever, even in doses 1000 times that pro¬
ducing its 'maximum' effect in control atria. When it
was added to the bathing medium it was seen to act as a
full antagonist against the effects of ISO and NA pro¬
ducing K values of 2.61 x 105 and 2.46 x 105 against
a
ISO and 1.5 x 106 and 1.38 x 105 against NA for chrono-
and inotropic responses respectively. This indicated that
Salb may not have the straightforward partial agonist
activity previously ascribed to it. In control atria,
the log dose - response curves for chrono- and inotropic
responses to ISO, NA and Salb were all shifted in a
parallel manner to the right by both selective and non¬
selective antagonists indicating a first-order f3-adreno-
ceptor interaction of all the drugs involved. Even responses
to Salb were parallel, though as seen from Fig 8 the
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'maximum' was depressed, indicating either that it
occupies all of the ^-adrenoceptors to evoke its sub-
maximal response or that there is some non-specific com¬
ponent of action that is susceptible to p-blockade. The
order of potency of the (3-blockers against the three
agonists was maintained in the 6-OHDA atria, except for
Salb. Since £3, -selective practolol (Pract) produced the
rank NA > ISO > Salb, (32-selective ICI 118 551 produced
Salb > ISO > NA and non-selective irreversible Ro-03 7894
produced ISO > NA > Salb for both chrono- and inotropic
effects, it would appear that both P', and p2 subtypes
coexist in guinea-pig atria subserving both chrono- and
inotropic responses to adrenergic agonists, otherwise
a single rank potency order for all of the (3-antagonists
would be expected. Since the EC^q values for ISO and NA
were unaltered by 6-OHDA pretreatment, there was no
evidence of a supersensitivity to exogenous catechol¬
amines as we had expected from the denervation super¬
sensitivity reports in the literature. The K
a values of
the highly-selective (32 antagonist (Bilski et al, 1980;
0'Donnel and Wanstall, 1980) and the irreversible non¬
selective antagonist Ro-03 7894 (Nicholson and Broadley,
1978) were unaltered by 6-OHDA depletion yet the values
of (3, -selective Pract were increased when measured
against both p1-selective NA and non-selective ISO.
It therefore appeared that the drugs in the study were
acting at different subtypes (differences in rank poten¬
cies) which are altered differently by 6-OHDA (K&
105
alteration by depletion). We therefore carried out a
similar series of experiments on reserpinised atria to
see whether we could confirm the results of other
authors or whether the anomalous results were due to our
handling of the preparations. We confirmed that a dener¬
vation supersensitivity occurs following reserpinisation.
Responses to ISO and Salb were both enhanced after
depletion but responses to NA were in fact depressed.
This confirms the results of Broadley and Lumley (1977)
who found that both rate and tension responses of guinea-
pig atria were shifted to the left by reserpine treatment.
Since they found no alteration in responses to histamine
2 +
or Ca ions the effect may be considered ^-adrenoceptor
selective. They also found supersensitivity to Salb but
theirs was manifested by an increase in the 'maximum'
produced, ours was not. Potentiation of rate responses
after reserpine has been shown in perfused hearts by
Westfall and Fleming (1968) but failed to show in the
isolated guinea-pig atria in the hands of Crout et al
(1962). Taylor et al (1974) claimed that reserpine
affected only rate responses. We fund both rate and
tension changes confirming the results of Westfall and
Fleming (1968) and McNeill and Schulze (1972) respectively.
The differences in observations may be attributable to
tissue trauma etc. In the case of Taylor er al, the
differences may be explained by their rate of atrial
pacing (60 beats/min above resting rate) which could be
too high (we paced at or just above resting rate - 210
beats/min) as if pacing is too fast, energy availability
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to follow the pace may become a limiting factor and
reduce the inotrqjic response. Tyramine and 6-OHDA both
failed to evoke a response in reserpinised atria indic¬
ating a large reduction in the residual amine pool as
was seen in the 6-OHDA denervated atria. The effects
of reserpine on the values of the non-selective ant¬
agonist Ro-03 7894 were decreased against ISO and NA
but unaltered against Salb indicating a decreased blocking
potency after reserpine. The selective (3., antagonist Pract
K values were increased against ISO and NA but again
a
unaltered against Salb. If receptor affinity is unaltered,
the supersensitivity to ISO and subsensitivity to NA
indicated that agonist efficacy is altered and this
change may take place beyond adrenoceptor level, eg. at
the second messenger stage. The anomalous data obtained
from the study suggests a dual action of Salb. It may
be that Salb acts on |32-adrenoceptors prejunctionally to
produce positive chrono- and inotropic effects via the
released NA (an indirect action) while acting on (3.,-
adrenoceptors as a full antagonist. This latter action
would therefore be apparent following denervation by 6-
OHDA. The supersensitivity to Salb following reserpin-
isation may indicate insufficient depletion of the intact
adrenergic neurones. The lhck of response to tyramine in
the reserpinised atria may indicate that too low a dose
was used to release residual pools. Our conclusions on
the actions of Salb are supported by Hayes et al (1982)
who found that both ISO and Salb significantly increased
107
3
the fractional release of H-NA from guinea-pig atria.
The widely-held opinion that Salb is a partial agonist
at cardiac adrenoceptors appears to require revaluation.
Bieth (1980) found in binding studies that Salb had zero
affinity for rat lung (32-adrenoceptors an(^ a significant
affinity for rat myocardial |3-adrenoceptors which agrees
in part with our conclusions. Baker et al , 1980) studied
^-adrenoceptor distribution in the canine heart and
found that receptors were disposed proportionately to
blood flow and the arrival of circulating catecholamines
rather than to adrenergic innervaion. The relatively
few adrenoceptors at the synapse were able to account for
near-maximal changes in cardiac performance. We support
this statement insofaras loss of innervation produced
great alteration in responsiveness to adrenergic agents.
Effects of chemical denervation by 6-hydroxydopemine on
responses of the guinea-pig trachea to adrenergic stimuli
We then examined the effects of 6-OHDA pretreatment on
the guinea-pig trachea where the ^-adrenoceptors are
thought to be of the p2-subtype. Spontaneous-tone prep¬
arations were used since in the carbachol-contracted
trachea, the concentration of carbachol employed may
dictate the degree of relaxation produced by (3-antagonists
(Buckner and Saini, 1974) and if agonists were to produce
sub-maximal responses, a high tone would exaggerate this
making EC,_q values redundant. Furchgott et al (1973)
found that the trachea can take up ISO and other amines
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by extraneuronal uptake and therefore blockers were
included in the Krebs'solution as in the atrial exper¬
iments. Salb was found to be a full agonist in the
trachea, producing a maximum response equal to that of
ISO and the |32-selective agonist procaterol (Proc).
The potency order for the three was ISO > Proc > Salb.
When Pv~> P2— or non-selective antagonists were employed
against the agonists, they all maintained the same rank
order of potency. This indicated that in the trachea the
agonists and antagonists are all acting at the same
receptor pool consisting probably of only one subtype.
Since this rank order of potency was retained after 6-
OHDA it would appear that the subtype is unaltered by
chemical denervation. The order of potency for the ant¬
agonists against all agonistswas propranolol > ICI 118
551 > butoxamine > practolol. This conflicts with the
order obtained by Levy and Wilkenfeld (1970)
who found practolol to be more potent than butoxamine.
Propranolol therefore appears to be very potent when
measured against |32-selective agonists. When the
values were calculated for the control and denervated
tracheae, after denervation the values for (32-selective
antagonists decreased while the others increased. It
therefore appears that denervation does produce some
alteration in tracheal responses to adrenergic agents




1) Both (3, and p2 adrenoceptor subtypes appear to co¬
exist in guinea-pig atria.
2) In intact tissues, both tyramine and 6-OHDA appear to
evoke positive chrono- and inotropic responses by an
indirect action.
3) Reserpinisation produces atrial supersensitivity to
adrenergic agonists, chemical sympathectomy by 6-OHDA
does not.
4) It appears that 6-OHDA pretreatment reduces the pre¬
junctional (32 —adrenoceptor population.
5) Salbutamol appears to have two actions. It seems to
exert its sympathomimetic effects by releasing endog¬
enous catecholamines to produce both positive chrono-
and inotropic effects while acting directly on the
P1-adrenoceptor as a full antagonist.
6) In guinea-pig tracheae, all ^-adrenoceptors appear
to be of the same (P2) subtype. The p-adrenoceptors
mediating relaxation responses to adrenergic agonists
do not appear to be altered by denervation and
therefore are probably not innervated.
Changes in cardiac p-adrenoceptors produced by 6-hydroxy-
dopamine pretreatment assessed by radioligand binding.
To ensure that binding studies were worth pursuing,
certain criteria for the binding sites had to be satis¬
fied. In many receptor binding experiments high affinity
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racemic ligands are used as tracers with differences
in binding affinities of the two isomers being ignired.
The resultant observed KD is therefore actually a hybrid
of Kp( +) and Kp(-) which can lead to a five-fold under¬
estimate of the active isomer KD (Burgisser et al, 1981).
We used (-)125I-pindolol (IPin) as our radioligand
because of its high specific activity and its non¬
selective (3-antagonism. The absence of a catechol group
on pindolol increases its specificity for (3-adrenoceptors
since it won't bind to non-receptor binding sites that
have a pronounced affinity for catecholamines and could
interfere with receptor determination (Lefkowitz, 1965).
A finite number of binding sites had to be established,
of rather high affinity. Thus, if increasingly higher
and higher concentrations of labelled ligand are added
to the microsomal membrane fraction of guinea-pig
hearts, label binding should be seen to increase up
to the point where all of the binding sites are :
occupied (saturation) and this was, in fact, found to
be the case - see Fig 11a. Scatchard analysis of such
a hyperbolic curve yields a linear plot with negative
slope as shown in part b. The term specific binding
usually refers to that component of ligand binding which
is displaceable by a high concentration of a oold ligand
- here we used 200UM ISO - and possessing the character¬
istics of true receptor binding. Non-specific binding
(NSB) refers to that component of ligand binding not
inhibited by high concentrations of the cold competitor
Ill
and which does not meet the criteria for true receptor
binding. This condition was also met as is shown in Fig
10. NSB increased linearly with total radioactivity
present and was not saturable and therefore does not
represent true receptor binding. NSB may include both
hydrophobic and hydrophilic non-stereospecific inter¬
actions (Wolfe et al, 1977). Its linear relationship
with radioligand concentrations makes it possible to
eliminate it from the binding data by simple subtraction,
and it was always less than 10% total binding. The
Scatchard plots of control versus 6-OHDA membrane
binding isotherms for IPin yield the binding site
density (Bmax) value. Combined atria and ventricles
were used and it may be seen that 6-OHDA pretreatment
produced an approximate doubling of the ligand binding
sites of the myocardial membranes. The control value
of 60 t 6.5 fmol/mg protein increased up to an average
of 111 ± 9.2 fmol/mg protein. There was no alteration
-in receptor affinity for the ligand caused by 6-OHDA,
both control and denervated tissues having an affinity
constant of 286pM. This corresponds with the results of
Yamada et al (1980) who found a significant increase
in p-adrenergic binding sites in the rat heart following
only 2 x 50mg/kg 6-OHDA treatments, with no alteration
in receptor affinity. They also found that the increased
receptor density was not proportionate to the degree of
increased chronotropic effects that they obtained.
Densities of receptor binding sites cannot therefore
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be simply equated with functional receptors. Having
established initial receptor binding criteria, a series
of displacement of specific binding experiments was
carried out. Fig 12 shows the results of additions of
a series of cold ligands to IPin incubates after
equilibrium binding had been established. When the
competing ligand was non-selective a uniphasic plot was
observed, but when the competing ligand was selective,
the resulting biphasic plot yielded information on the
adrenoceptor subtypes present. Computer analysis of
the data calculated the relative percentages of the two
subtypes from the two components of the ligand binding
plot, The iterative procedure of the computer modelling
programme finds the best fit for the biphasic Hoffstee
plots whether for two or more compartments and no trans¬
formation of the data is required, therefore fewer ass¬
umptions need be made and fewer errors are introduced.
Each of the independent components is then assumed to
obey simple Michaelis-Menten (mass action) kinetics. The
size of the contribution of each component would then
be due to the relative affinity of the drug for that sub¬
type and the relative number of the subtype. Table 6
shows the calculated percentage distributions of the (3.,-
and p2-subtypes and, as was expected, the major subtype
present in both atria and ventricles is (3,. Following 6-
OHDA pretreatment there was a significant increase in
the proportion of p, adrenoceptors in both atria and
ventricles. Since the limits of the computer modelling
113
technique have been placed by De Lean et al (1982) at
90% : 10% high and 10%:90% low affinity separation,
perhaps in a few of the cases following denervation the
results are getting very near the limits of resolution.
The existence of two adrenoceptor subtypes is in agree¬
ment with the findings of Carlsson et al (1972) when they
found that two adrenoceptor subtypes may coexist on the
same organ mediating the same physiological response. In
control atria :(32 was approximately 70:30 and in control
ventricles the ratio was higher at 76:24. In the 6-OHDA
atria and ventricles both ratios were significantly raised
to 81:19 and 85:15 respectively and this increased Pz
population raises the possibility that the (32 adrenoceptors
identified by our study are prejunctional in origin
carfied on neuronal membranes in our preparation. This
may explain the fact that while many authors have shown
heterogeneity of {3-adrenoceptors in tissues such as lung
(Barnett et al, 1979) it has generally been accepted
that guinea-pig ventricular ^-adrenoceptors are all of
the (3, -subtype (Hedberg et al, 1980). A series of
kinetic experiments was carried out in the same manner to
see whether denervation altered the kinetic properties
of binding sites. In both sets of membranes, the 'on'
reaction was too fast to measure sufficient points
accurately but the 'off' reaction followed quite a long
time course. Again selective agonists and antagonists
produced biphasic plots and two rate constants could be
calculated for each, presumably on the basis of differences
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between the receptor subtypes. The rate constants
remained unaltered by 6-OHDA confirming the earlier
finding that receptor affinity is unaltered by 6-OHDA.
Biphasic dissociation kinetics are not a unique feature
of adrenoceptor binding. Similar kinetics have been
described for several ligands in different receptor
systems eg. the thyrotropin receptor (Verrier et al, 1974)
and the acetylcholine receptor (Boyd and Cohen, 1980).
It has often been stated that the intrinsic activity of
the ^-adrenoceptor agonist may be regarded as its ability
to activate the adenylate cyclase system of a cell (Kent
et al, 1979) . The activation appears specific for the
(3-adrenoceptor since the order of potency for stimulation
is ISO > Ad >NA and the response is specifically
blocked by propranolol and not by phentolamine (Lefkowitz,
1977) . In guinea-pig atria the ability of ISO to increase
cellular cyclic AMP is related to its inotropic effects
(Osnes and 0yes, 1975). While most sources agree on this
for the (3-adrenoceptor, the case for the (32-adrenoceptor
has not been quite so clearly defined. Minneman et al
(1979) showed that |32-selective agonists produced no
alteration in cyclic AMP levels while evoking marked
chronotropic responses. Freyss-Beguin et al (1983)
correlated (32 agonist ability to elevate heart rate
with their ability to elevate cyclic AMP levels of rat
heart cell cultures confirming the findings if Hazeki
and Ui (1980) who showed that Salb and Proc (both (32)
both elevate cyclic AMP levels in dispersed heart cells.
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However, since none of the (3,- and (32-selective drugs are
totally selective, a cyclic AMP effect may not necess¬
arily be produced by a drug's 'preferred' receptor.
Mainly though, an agonist's ability to activate the
adenylate cyclase system closely correlates with the
proprtion of high affinity states of the adrenoceptor
2 +
formed in its presence. Mg ions are required for the
formation of the high affinity receptor-agonist complex
(Hoffman and Lefkowitz, 1980) and this was included in
the buffers at the appropriate concentration. Guanine
nucleotides have no effects on the competition curves
of antagonists and antagonist binding does not involve
adenylate cyclase activation as agonist binding does. Fig
28 describes the proposed model for agonist binding.
The agonist or hormone (H) binds to the receptor (R)
to form a low-affinity, freely-reversible complex. This
may then combine with a component of the adenylate cyclase
system forming a ternary complex which is intermediate
and facilitates adenylate cyclase activation by GTP. GTP
then dissociates the high-affinity slowly-dissociable
H-R complex reverting the adrenoceptor back to its low-
affinity state and activating the adenylate cyclase
system (Hoffman and Lefkowitz, 1980). The high affinity
binding state of the adrenoceptor can therefore be con¬
verted to its low affinity state by the addition of GTP
nucleotides to the incubate. Lefkowitz et al (1978) pro¬
posed a rank ore: r of potency for nucleotide production
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Kent et al (1979) found that the conversion of high
affinity to low affinity binding sites by the nucleotide
was dose-dependent and that at 10~4M GTP all of the
binding sites were in the low affinity state. We there¬
fore used Gpp(NH)p at 10~4m which is a stable non-
hydrolysable GTP analogue. In control and denervated
membranes alike both |31 - and |32-seiective agonist dis¬
placement curves were shifted by the addition of the
nucleotide. The same order of shift was found after 6-
OHDA indicating an unchanged propensity of the p-adreno-
ceptors to be converted to their low affinity binding
states. Nucleotide linking of the receptors is apparently
unaltered by denervation and it appears that the KH/KL
ratio of the binding sites is not governed by organ
innervation.
CONCLUSIONS:
1) Binding characteristics of the radioligand (-)125IPin
appeared to satisfy criteria that the binding sites
were representative of the (3-adrenoceptor.
2) Sympathectomy by 6-OHDA produces a doubling of guinea-
pig heart binding sites with no alteration in affinity.
3) 6-OHDA pretreatment produced an alteration in atrial
|3, : (32 from 70:30 to 81:19 and in the ventricles from
76:24 to 85:15. It's possible that the (32-adrenoceptors
are present on neuronal membranes in the preparation.
4) The interconversion of high and low affinity states
of the binding sites is unaffected by sympathectomy.
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5) The data of the increased (3, population agrees with
the isolated atria data so far as Salb is concerned
but not the other agonists since no supersensitivity
was observed. It may therefore be that"! binding sites
identified by radioligand binding do not directly
represent a functional pharmacological or physio¬
logical receptor.
The effects of {3-blockade on conscious dog ECG parameters
during alteration of thyroid state.
We then went on to investigate (3-adrenoceptor mediated
response alteration by thyroid state. The model was the
conscious dog ECG. It has long been known that a
tendency towards cardiac dysrhythmias is decreased in
myxoedema and that apart from the occasional extra-
systole associated with a very low HR, cardiac irregular¬
ities are rare. In thyrotoxicosis, however, atrial
fibrillation and other supraventricular dysrhythmias are
common. In both cases the alterations in cardiac per¬
formance are largely reversible by appropriate therapy.
Freedberg et al (1970) showed that atrial preparations
from rabbits chemically or surgically made hypothyroid
displayed electrophysiological changes in an anti-
dysrhythmic direction. They also noted that there was no
alteration in the resting potential or action potential
voltages or the rate of rise of action potential but
the duration of the repolarisation phase of the action
potential was greatly prolonged, the converse being
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demonstrated in hyperthyroidism. Prolongation of the
duration of action potential and therefore a consequent
increase in refractory period is the Class III anti-
dysrhythmic action. Sotalol possesses this class of action
and has been shown to protect urethane-anaesthetised
guinea-pigs against ouabain-induced ventricular fib¬
rillation (Singh and Vaughan Williams, 1970). In doing
so it greatly prolonged the duration of action potential
and the QT segment of the ECG record. There is much
conflicting evidence in the literature as to whether
alteration of thyroid state can affect cardiac responses
to catecholamines either by a direct action of the thyroid
hormones on the heart or by increasing cardiac sensitivity
to catecholamines. When we shifted the log dose - response
curves of HR response to ISO with the three antagonists
of the study, sotalol, propranolol and nadolol all
produced a shift to the right of a parallel nature. This
indicates that over the dose range employed all three were
acting in a competetive manner to inhibit chronotropic
responses to catecholamines. The resulting dose ratio
values (DR) were subsequently plotted against their
effects on the dog ECG so that the results were ex¬
pressed in terms of their p-blocking potencies their
relative blocking effects being sotalol = 1, propranolol
= 8.65 and nadolol = 134. These results agree with those
of Gomoll and McKinney (1974) in the chloralose-anaesth-
etised dog where sotalol had 1/6 - 1/8 If the activity
of propranolol in blocking HR responses to cardio-
accelerans nerve stimulation, but disagree with those of
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Lee et al (1975) who found that nadolol was only five
times as potent as propranolol in blocking guinea-pig
HR responses to ISO in vivo. Since many authors have
reported an increased response to catecholamines after
T4 treatment, we repeated the log dose - response curves
when the dogs were made both hypo- and hyperthyroid (by
carbimazole and T3 pretreatments respectively). We found
no significant changes in HR response to ISO in either
of the two treatments and all three antagonists pro¬
duced the same degree of shift as in controls. We ther-
fore disagree with the findings of Hashimoto and
Nakashima (1978) who demonstrated an increased response
of guinea-pig atria to ISO by T4 treatment while a-adreno-
ceptor mediated responses were depressed. Margolius and
Gaffney (1965), however, did report similar findings
to ours when they showed that T4 or 1251 treatment of
dogs produced no effects on arterial blood pressure or
responses to endogenous or exogenous catecholamines.
Teoh et al (1974) found that the increased HR of thyro¬
toxic patients reverted to normal following specific
anti-thyroid treatment but was only partially decreased
by adrenergic blockade by propranolol or by reserpine.
They therefore postulated that the sinus tachycardia
of thyrotoxicosis is due to combined direct effects of
thyroid hormones on the heart and also to an increased
sensitivity to catecholamines. This was supported by
Canary et al (1957) who suggested that since adrenergic
blockade only slowed the HR but did not revert it to
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normal, the resultant tachycardia of thyrotoxicosis must
be due to a combination of direct thyroid hormone effects
and an increase of adrenergic sensitivity, Symons et al
(1979) demonstrated a direct myocardial effect of thyroid
hormones to produce chrono- and inotropic effects.
While we found that resting HR was significantly
increased by T3 treatment, responses to catecholamines
were not. Neither was there a decrease in activity after
carbimazole treatment. We also found QT interval to be
increased by T3 treatment which was unexpected although
Sandler (1959) also found this but it was refuted by
Freedberg (1967) who reported a QT shortening. This
shortening of the electromechanical systole (QT) often
reported in thyrotoxicosis is mainly due to a decreased
pre-ejection period, left ventricular ejection time
remaining unaltered. Some authors have attributed this
to a shortened isovolumetric contraction ti-me reflecting
a state of enhanced myocardial contractility (Mazzaferri
and Lewis, 1978; Bough et al, 1978). Conversely, Bough
et al showed that systolic time interval was proportional
to the degree of severity of myxoedema and could be used
as an index of the disorder. We found no significant
ahanges in the duration of the PR interval unlike Gordan
et al (1944) who showed a prolongation of PR interval in
thyrotoxicosis. Our observations confirm those of
Sandler (1959) and Chia et al (1971) where no alteration
in the PR duration was found. THe QT/RR ratio which we
used as an index of 'refractoriness' was also increased
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by T3 treatment. The hypo- and hyperthyroid states were
taken as achieved when the electrophysiological and
physical parameters stabilised. We measured plasma T3
and T4 levels during each stage to see whether there was
correlation berween ECG changes and hormone levels. In
control dogs, T4 levels were high, being approximately
five times higher than T3. The differences were of the
same order as those reported by Cavalieii and Pitt-
Rivers (1981) who demonstrated that T4 binding to plasma
proteins has ten times the affinity for T3, the binding
being non-covalent and rapidly reversible. The principle
binding proteins involved are albumin, prealbumin and
thyroglobulin. T4 depression was seen in both of the
drug treatments while T3 levels were significantly
increased during T3 treatment. Since Riddel et al (1980)
found no significant alteration in the half-life of
plasma propranolol in either hypo- or hyperthyroidism,
we did not find it necessary to alter our programme of
infusions. A 30 minute infusion of sotalol (final dose
5mg/kg) produced a significant increase in PR interval
and this was also noted by Piessens et al (1974). Since
this is often associated with a Class I antidysrhythmic
action representing as it does an increase in conduction
time from the sino-atrial node to the atrio-ventricular
complex, and sotalol has only 1/300 the local anaesthetic
activity of propranolol, the prolongation must be
caused by some other property of sotalol. This prolong¬
ation of PR interval was significantly depressed by T3
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treatment. The effects of sotalol on QT prolongation were
much more marked. THe QT prolongation effect was dep¬
ressed by carbimazole treatment but enhanced by T3. Since
myxoedema is usually associated with a prolonged AP
duration and thyrotoxicosis with a shortened AP duration,
this alteration of sotalol potency for QT prolongation
in ^altered thyroid state appears to be advantageous.
This would especially be true in hyperthyroidism where
atrial fibrillation produced by shortening of the
AP duration is life-threatening. Sotalol had no sig¬
nificant effect in reducing resting control or carbimazole
HR. Again, however, the effect was more marked in T3
treatment. The significant trend of a dose-dependent
increase in QT/RR ratio in control dogs was unaltered
by carbimazole but T3 treatment greatly increased the
effects of sotalol on the ratio. Since we used the ratio
as an index of cardial 'refractoriness' it again appears
that the (3-blocker sotalol is highly beneficial in the
hyperthyroid state. When propranolol was infused over a
30 minute period (total dose 2mg/kg) a different set
of trends emerged. The effects of propranolol on PR
interval were more marked than those of sotalol and the
effects were depressed by both T3 and carbimazole. The
effects on QT interval prolongation were very weak when
compared to those of sotalol but were significant and
dose-dependent., being unaltered in either thyroid
state. Propranolol was less effective in reducing the
resting HR than sotalol which was a result in the opposite
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direction from that predicted from their relative (3-
blocking potencies in blocking HR responses to ISO. The
HR reduction was even less obvious after T3 and could be
taken to indicate a direct hormonal action on the heart
insensitive to (3-blockade and hence the more effective
actions of sotalol to reduce HR are probably due to its
Class III activity rather than its (3-blocking property.
This does not agree with Howitt et al (1963) who found a
significant reduction in supine HR of the thyrotoxic
patient with p-blockade. The weak HR effects of both
antagonists here is supported by Shanks et al (1974) who
found that neither produced any effects at all on the
resting HR of healthy subjects though Kofi-Ekue et al
(1970) found that they were both of a similar potency in
producung a significant deduction in exercise-induced
tachycardia in man. Propranolol produced a reduction in
the QT/RR ratio indicating a reduced refractoriness of
the heart which was unaltered by either treatment. It
therefore seems that propranalol would aggravate the
condition ofAPD shortening jnthyrotoxicosis and may even
act to precipitate fibrillation via further reduction
of the effective refractory period. Nadolol infusion over
a 30 minute period (final dose 5mg/kg) produced no
alterations in the ECG parameters whatsoever. This supports
the observations of Lee et al (1975) who infused nadolol
into conscious dogs up to 150 mg/kg and found no alter¬
ations in the ECG. Nonetheless, from its extremely high
(3-blocking potency against ISO we had expected some ECG
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changes, especially as Vukovich et al (1976) reported
that nadolol produced a reduction or remission in
subjects with frequent ventricular or supraventricular
ectopic beats and cardiodysrhythmias. From this |3-
blocking data it was shown that all three antagonists act
in a competetive manner. Their effects on the ECGs are
different, however, It would appear from the thyroid
state data that sotalol has many advantages over the more
usual drug of choice propranolol to combat the resultant
dysrhythmia of thyrotoxicosis since we have shown it to
be more effective in reducing HR, prolonging QT interval
and increasing the effective refractory period and hence
reducing the risk of reentry dysrhythmias and atrial
fibrillation which occurs in 10% of patients with
clinically overt thyrotoxicosis (Forfar et al, 1979).
In the euthyroid patient, however, a prolongation of QT
interval is not necessarily beneficial. Neuvonen et al
(1981a) found that euthyroid subjects receiving lOmg/kg
sotalol per day exhibited QT prolongation of up to 150
msec (35%) compared to their pre-sotalol values. Prop¬
ranolol on the other hand appears to act in a detrimental
fashion in the hyperthyroid state by reduction of ref¬
ractory period.This though may prove to be beneficial
in the hypothyroid subject and these factors of the |3-
blocker effects should be taken into account when
deciding upon a drug of choice for controlling dys¬
rhythmias. Neuvonen (1981a) showed that sotalol produced
significant prolongation in QT interval. In patients who
126
took an overdose of sotalol, however, the QT interval
could be up to 172% elevated (1981b) accompanied by
severe tachydysrhythmias and this was concurrently
reported by Kontopoulos et al (1981). A good correlation -
was found between the degree of prolongation, the tachy-
dysrhythmia and the serum sotalol concentraion and in
almost all cases of torsade de pointes (atypical vent-
tricular tachycardia) an increase in QT interval pre¬
ceded the tachycardia (Krikler and Curry, 1976). The
QT interval can only be indicative of action potential
duration (APD) if all of the ventricular fibres are
firing synchronously. Therefore any condition producing
asynchronous activation of the ventricular muscle fibres
will produce prolongation of QT interval without
affecting APD. Such conditions as in the ' long QT
syndrome' are associated with ventricular dysrhythmias
in contrast to a prolonged APD which, whether drug- or
hypothyroidism-induced is associated with stable
rhythm.
CONCLUSIONS:
1) Alteration of thyroid hormone levels produces electro¬
physiological changes of the canine heart.
2) Sotalol but not propranolol was effective in lowering
resting HR in hyperthyroid state, possibly by Class III
actions.
3) In the hyperthyroid state, sotalol is highly potent
in increasing QT/RR ('refractoriness') ratio.
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4) Nadolol produces no alteration of the canine ECG.
5) Sotalol would appear to be a drug of choice in cardiac
dysrhythmia complicated by thyrotoxicosis.
The effects of (3-blocker overdose on the anaesthetised rat
From Table 9 it was shown that there was no significant
correlation between (3-blocker sales and the incidence
of self-poisoning. The clinical features of (3-blocker
intoxication reported in these cases include hypotension,
bradycardia, low output cardiac failure, cardiogenic
shock, respiratory depression, convulsions and coma
(Khan and Muscat-Baron, 1977). It therefore seems that
a large central nervous system effect is produced on
overdose and effects on the central nervous system are
common side-effects during (3-blocker therapy. The three
drugs of the previous study were therefore infused into
urethane-anaesthetised rats and the ECG traces monitored
until death occurred. As before both sotalol and prop¬
ranolol had a significant prolongatory effect on PR
interval with no change produced by nadolol. This time,
however, nadolol did produce an extremely weak effect
on QT interval. These effects on PR and QT intervals
were unaffected by ventilation indicating a direct myo¬
cardial depressant effect. When we compared the relative
fatal doses of the three drugs the apparent order of
toxicity was propranolol > nadolol > sotalol. Since we
had shown in the conscious dog that the DR values of
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the three were very different, and since as previously
explained we had extrapolated th ese values to the
anaesthetised rat, these toxic doses are better ex¬
pressed in terms of DR as shown in Fig 24. The same
difficulties were obviously experienced by Imms et al
(1977) in evoking rat cardiac responses to exogenous
catecholamines when they stated * it is possible that the
cardiovascular system of the rat contains different adreno¬
ceptors from those of other species and which respond
differently to stimulation by catecholamines'. However,
in 1979 they induced an increased HR response in the
anaesthetised rat to ISO when they compared the blocking
effects of practolol and propranolol on HR and peripheral
resistance. Their results led them to conclude that there
are both (3, and (32 sub-populations of adrenoceptor on
the rat myocardium. Expressing our results in terms of
DR produced a rather different order of toxicity with
propranolol >✓ sotalol >> nadolol, propranolol and sot-
alol having approximately 130 times the toxicity of nad¬
olol. This is a much greater toxicity difference than
that reported by Lee et al (1975) who found that prop¬
ranolol was 20 - 30 times as depressant on the canine
myocardium in vivo. However, the initial observation
that nadolol appears highly non-toxic agrees with their
later work (1978) when they introduced a 'myocardial
safety index' (dose producing 50% reduction in dP/dt /
dose producing 50% HR reduction) and found that nadolol
was 2000 times as safe as propranolol having the least
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propensity of an entire series of (3-blockers to produce
direct myocardial depression in the atherosclerotic
rabbit. Since the drugs have very different effects on
the ECG we then examined the electrophysiological
changes preceding death to ascertain the mechanism by
which (3-blocker overdose can precipitate total cardiac
failure. From the ECG traces taken during sotalol inf¬
usion (3.6 mg/min) it may be seen that although venti¬
lation greatly prolonged the survival time of the animal,
similar ECGs were produced. None of the rats exhibited
dysrhythmias up until the time of death. A dose-dependent
bradycardia was produced by the infusion but every P
wave was followed by a QRS complex. Ventilation alone
at a constant volume increases survival time by a factor
of 4.3. In neither case did the gross QT prolongation
induce a tachydysrhythmia. This disagrees with the
observations of Neuvonen et al (1981a,1981b) who found
QT prolongation in sotalol overdose was proportional
to the incidence of ventricular tachydysrhythmias al¬
though they presumably found this in subjects already
receiving sotalol therapy which may account for the more
severe reactions. Their observations supported those
of Elonen et al (1979) who also found susceptibility
to ventricular extrasystole proportional to QT prolong¬
ation in sotalol overdose. The same overall pattern
was observed with nadolol infusion. This time the
survival time was increased by a factor of 10.6 by vent¬
ilation of the animal and in both cases no dysrhythmias
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were observed up until the moment of cardiac death.
Death occurred much more quickly in the case of propran'r.
olol infusion and in this case survival time was pro¬
longed by a factor of 9.2. However, in this case an
atrio-ventricular block occurred very quickly and was
still present in the ventilated animals and this is
probably a product of its membrane-stabilising effects.
From Fig 24 it had already become apparent that death
was not produced as a result of a straighforward {3-
blocking action or else the correction of the data for
their respective DR values would have produced equal
effects. The fact that ventilation alone produced such
a dramatic increase in survival time raised the poss¬
ibility that part of p-blocker toxicity may be via
respiratory depression. When blood gas data was meas¬
ured throughout the infusion periods it became obvious
that in all unventilated animals blood pC02 rose greatly
prior to death with a concomitant massive drop in p02.
This was not observed in the ventilated experiments. It
therefore appeared that in the unventilated rat all three
p-blockers were acting by some mechanism to depress
respiration. Mustchin et al (1965) found that a single
oral dose of propranolol (80mg) in humans significantly
depressed respiratory responses to C02 with a reduction
in initial respiratory pressure. This was taken as
evidence of a central depressant effect. This was
supported by Campbell et a 1 (1981) who shoved a depress¬
ion of respiratory response to C02 produced by propranolol.
It could well be that the combination of hypoxia and
acidaemia was a contributory and even a major factor in the
cardiac arrest seen with relatively low doses of (3-blockers
in unventilated animals.
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Perhaps in that case the three blockers in our study
were producing respiratory depression by this prop¬
osed central action. It then became necessary to eval¬
uate their pharmacokinetic properties. One of the major
determinants of a drug's pharmacokinetic profile is its
liposolubility. In this respect, propranolol has
approximately a 400 times greater distribution coeff¬
icient than sotalol or nadolol since propranolol is lipo¬
philic and the other two are lipophobic (Woods and
Robinson, 1981). The blood - brain barrier acts as a
simple lipid membrane (Mayer et al, 1959) and therefore,
as expected, lipid-soluble drugs penetrate that way into
the central nervous system to a much higher degree than
water-soluble drugs. Propranolol has been demonstrated
to be taken up centrally and brain : periphery plasma
ratios of 15 : 1 have been demonstrated by Myers et al
(1975) in both animal and human studies. Since only the
free unionised species of the drug can cross a lipid
membrane this partition coefficient becomes the most
important factor in determining the distribution of the
three antagonists since they all have approximately
equal pKa values in the range of 9.45 - 9.8 (Turner,
1983) and in that case we would have expected a toxicity
order of propranolol > nadolol > sotalol. If central
respiratory depression is occurring it may be that the
drugs are able to enter the ventral nervous system with¬
out having to cross the blood - brain barrier. Dev and
Loeschcke (1979) demonstrated respiratory depression by
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intravenous hexamethonium in the hyperventilation resp¬
onse to nicotine applied topically to the caudal medulla.
Since hexamethonium is a quaternary ammonium compound
and lipophobic, in order to produce a medullary chol¬
inergic blockade it must have penetrated the central
nervous system by another route. A central effect for all
three antagonists cannot therefore be entirely ruled
out. It is unlikely that respiratory depression is due
to direct effects on the distal airways mediating
bronchoconstriction since this was found to be negligible
by Campbell et al (1981). Heistad et al (1972) and Keltz
et a}. (1977) showed that the increased minute volume
produced by adrenergic agonist infusion is blocked by
propranolol but also by ventilating with 100% 02.
Adrenergic stimulation of ventilation may therefore be
partly mediated via the peripheral 02 chemoreceptors
and this may be a possible site of action whereby the
^-adrenoceptor antagonists can produce respiratory
depression.
CONCLUSIONS:
1) Isoprenaline produced no HR response in the anaesth¬
etised rat.
2) Neither nadolol nor sotalol produced dysrhythmias
preceding death from overdose but propranolol
produced a 2:1 atrio-ventricular block.
3) Ventilating the anaesthetised rat at a constant
volume of air greatly increased the lethal dose of
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(3-blocker required.
Death due to p-blocker intoxication appears to be
due to respitatory depression and this is reflected
by the blood gases and the fact that a much higher
lethal dose is required in the artificially-ventilated
rat.
Respiratory depression by p-blockers appears to be
independent of their pharmacokinetic properties and
both central and peripheral respiratory depression
mechanisms are possible.
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SECTION V : APPENDIX
Table A.
The effects of sotalol, infused at a rate of 0.167 mg/kg/min,
on HR, PR and QT intervals and QT/RR ratio in four conscious
dogs. Each test was carried out in duplicate and the two
test runs are shown for each dog. Recovery time of several
days was allowed between tests. Where S.D. values are shown,
these are calculated from a 6-beat sample of the ECG
record at each time stated.
Tire ftfiSO A P!4 QTiSO Atjr W AH* OT/W A QT/W
(miro) (mse:)
...
(msec) (msec) (msec) (bts/nrin)
0 105i4 _ 21314 . 90 0.319 .
1 111 i4 6 21714 4 85 S 0.307 -12
2 114 111 9 227 1 6 14 69 -21 0.261 -58
5 11216 7 23114 18 82 -8 0.316 -3
10 ,11616 11 239 1 2 26 89 -1 0.354 35
15 11614 11 246 1 3 33 77 -13 0.316 -3
20 10914 4 244 1 4 31 78 -12 0.317 -2
2S 10814 3 25313 37 71 -19 0.296 -23
30 10914 4 259 1 2 46 68 -22 0.293 -26
0 41214 . 235 1 5 . 70 _ 0.Z74 .
i ' B12 £ 4 - 239 1 3 4 59 -11 0.235 -39
2 41312 1 24714 12 55 -IS 0.226 -48
5 U4i3 2 259 1 7 24 51 -19 0.223 -54
10 hl4il 2 279 1 4 44 50 -20 0.232 -42
15 11313 1 284 1 4 49 52 -18 0.246 -28
20 )12i2 - 292 i6 57 64 -6 0.311 37
25 11013 -2 297 1 9 62 73 3 0.361 87
33 111 12 -1 307 1 4 72 66 -4 0.338 64
Ti«e fft 1 SD API Tt ♦ so AQT HR 4 Kit QT/RR A ffT/fR
(nint (Atec) (AS«C ) («««c) <A(fC) (bit/Air )
0 10? _ 2l4i3 _ 100 _ 0.337 _
1 10413 -3 21017 -4 ? 8 -2 0.334 -21
2 10414 -3 21412 - ?5 -5 0.33? -11
5 11013 1 21 414 2 88 -12 0.317 -40
10 112K 3 22313 It 83 -17 0.311 -44
13 11312 4 21314 21 77 -23 0.304 -31
20 11413 3 24 414 30 73 -23 0.303 -32
23 11414 7 24413 32 74 -24 0.312 -43
30 11314 4 24717 33 81 -1? 0.333 -24
0 10f 13 . 20413 . ?4 - 0.330 -
1 112H 3 21013 4 IS -8 0.308 -22
2 11312 4 21213 4 79 -17 0.27? -31
3 11813 ? 22013 14 8? -7 0.324 -4
10 11413 7 22012 23 45 -31 0.248 -82
13 11314 4 23714 31 74 -20 0.300 -10
20 11 TH 10 24114 35 73 -23 0.2?3 -37
23 120H 11 24713 41 74 -22 0.303 -23
















A W QT/RR A QT/RR
0 129 ±7 223 1 3 _ 96 _ 0.353 _
1 13215 3 225 1 3 2 71 -25 0.353 -
2 12614 -3 23818 156 60 -36 0.282 -71
4 12514 -4 24915 26 68 -28 0.250 -103
6 134 14 5 250 1 4 27 73 -23 0.282 -71
10 13518 6 25815 35 76 -20 0.315 -38
16 13219 3 39516 42 72 -24 0.334 -19
25 136111 7 25519 32 62 -34 0.305 -48
34 13817 9 267120 44 62 -34 0.275 -78
38 14114 12 300 18 77 71 -25 0.357 4
40 137 16 8 29918 76 69 -27 0.345 -8
0 12917 _ 249 1 3 _ 73 _ 0.304 _
1 13118 2 250120 1 57 -16 0.236 -68
2 13215 3 244110 -5 62 -U 0.253 -51
4 13515 6 299 1 3 20 57 -16 0.255 -49
6 13815 9 276110 27 73 - 0.335 31
8 13615 7 267120 18 51 -22 0.228 -76
10 14216 13 277130 28 50 -23 0.231 -73
12 14213 12 29116 42 55 -18 0.268 -36
14 14318 14 30213 53 50 -23 0.252 -52
16 13919 10 303 1 4 54 55 -18 0.200 -24
18 139113 10 31111 62 63 -10 0.327 23
20 138110 9 309 1 8 60 51 -22 0.261 -43
22 13916 10 31919 70 58 -15 0.307 3
30 14116 12 30416 55 65 -8 0.329 25













AiF CT/RR A QT/RR
0 11613 21114 108 0.370
1 114*4 -2 21314 2 94 -14 0.334 -44
2 11714 1 21827 7 80 -28 0.292 -06
5 12123 . 5 22717 16 77 -31 0.293 -65
10 12225 6 23417 23 77 -31 0.301 -77
15 12322 7 27 68 -40 0.268 -110
20 12225 6 24012 29 79 -29 0.317 -61
25 L2424 8 24326 32 77 -31 0.313 -65
30 12624 10 24723 36 82 -25 0.336 -42
0 11824 _ 21923 80 0.200
1 12125 3 225*5 6 85 5 0.318 38
2 12324 5 228*5 9 77 -3 0.293 13
5 12625 8 236*5 17 67 -13 0.264 -16
12 12826 10 251*2 32 67 -13 0.279 -1
15 13224 14 25724 38 78 -2 0.336 56
20 12725 9 26026 41 76 -4 0.330 50
25 13228 14 26223 43 68 -12 0.298 18
30 12121 3 25323 44 60 -23 0.261 -19
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Table B.
The effects of sotalol, infused at a rate of 0.167 mg/kg/min,
on HR, PR and QT intervals and QT/RR ratios in four conscious
dogs pretreated with carbimazole.
Where S.D. values are shown, these are calculated from
















0 118 ± 3 _ 21314 _ 96 _ 0.342 _
1 12113 3 21812 5 87 -9 0.316 -26
2 12016 2 22016 7 66 -30 0.241 -101
5 13011 12 22417 11 71 -25 0.256 -76
10 12914 11 23814 25 62 -34 0.254 -88
15 13215 14 24413 31 53 -43 0.217 -125
20 13114 13 244 1 3 31 77 -19 0.311 -31
25 13013 12 24814 35 52 -44 0.215 -127













AHR QT/RR A QT/RR
0 12612 - 21812 - 53 - 0.187 -
1 12213 -4 220113 2 60 7 0.218 31
2 12114 -5 22715 9 53 - 0.203 16
5 141HO 15 23515 17 46 -7 0.179 -8
10 145110 19 24016 22 37 -16 0.148 -39
15 15016 24 24914 31 47 -6 0.195 8
20 146112 20 25416 36 51 -2 0.218 31
25 140IS 14 25316 35 48 -5 0.204 17














































































0 11715 - 21 4 ±3 - 89 - 0.317 -
1 1 18 ±2 i 2!7±6 3 95 6 0.343 26
2 12111 4 219—4 5 76 -13 0.277 -40
5 12212 5 223 ±2 V 82 -7 0.305 -12
10 12412 7 235±4 21 73 -16 oCO.N<S> -31
15 12315 6 237±4 23 77 -12 0.304 -13
20 124-3 7 240-2 26 73 -16 0.292 .it
25 118 ±7 1 239 ±1 25 74 -15 0.295 - i 3




The effects of sotalol, infused at a rate of 0.167 mg/kg/min,
on HR, PR and QT intervals and QT/RR ratio in four conscious
dogs pretreated with triiodothyronine. Each test was carried
out in duplicate and the two test runs are shown for each
dog. Recovery time of several days was allowed between tests.
Where S.D. values are shown, these are calculated from a














A IF or/PR A ot/PR
0 1181.7 _ 22016 _ 106 _ 0.550 _
1 11615 -2 25714 47 87 -19 0.531 -19
2 117 18 -1 27116 51 81 -25 0.532 -18
5 11817 - 292111 72 84 -22 0.618 68
ID 11916 1 206 15 66 102 —4 0.674 124
15 11614 -2 29716 77 109 3 0.679 129
20 12715 9 29715 77 104 -2 0.623 73
25 12716 9 340115 120 105 -1 0.668 118
3D ill9 18 1 323 13 103 103 -3 - -
0 108110 _ 221 16 _ 150 _ 0.391 _
1 107 112 -1 246*7 25 129 -21 0.307 —4
3 10614 -2 257 110 36 124 -26 0.*4DD 9
5 107 15 -1 251 15 30 140 -2 0.407 16
10 014 14 6 267 111 46 151 1 0.408 97
15 [ill 17 3 260 19 39 157 7 0.540 149
20 QJ5 14 7 209 116 68 131 -19 0.516 125
25 11013 2 272 17 51 147 -3 0.596 205











A HR or/PR A QT/RR
0 [ill ±2 _ 258 1 4 _ 134 _ 0.575 _
1 11016 -1 26215 4 134 _ 0.506 •JO.
2 114 ±3 3 26715 9 129 -5 0.573 -i2
5 11113 - 273 1 4 15 131 -3 0.598 ;23
10 114 ±3 3 20917 31 110 -24 0.532 —43
15 111 ±2 - 209 1 7 31 113 -21 0.547 -28
2D 114 ±3 3 31614 58 105 -29 0.550 -25
25 111 ±2 - 29714 39 105 -29 0.521 -54
3D 115 ±4 4 32016 62 130 -4 0.692 117
0 10014 . 269 1 5 _ 125 _ 0.545 _
1 111 11 3 27013 1 144 19 0.646 101
2 112i 2 4 277 18 8 141 16 0.651 106
5 106 i 4 -2 282i 10 13 161 36 0.755 210
10 112 1 4 4 313 1 4 44 121 -3 0.250 -295
15 115 1 4 7 332 1 5 63 104 -21 0.578 33
3D 111 11 3 334 1 4 65 107 -18 0.598 53
25 11012 2 334 1 4 65 108 -17 0.602 57





Tine PR±SD o PR QT±SD A QT HR MR QT/RR AQVRR
(nins) (nsec) (nsec) (usee) (nsec) (bt/nin)
0 112 —2 _ 227^3 _ 130 - 0.492 -
1 113 —2 1 231 ±4 4 125 -5 0.481 -11
2 112-2 - 23515 8 121 -9 0.474 -18
5 110±1 -2 254 14 27 128 -2 0.542 50
10 114 ±2 2 26911 42 122 -8 0.547 55
15 113 ±3 1 280 18 53 110 -20 0.513 21
20 111 ±3 -1 287±4 60 116 -14 0.555 63
25 113—1 1 29515 68 97 -33 0.477 -15
30 113—1 1 299 15 72 96 -34 0.478 -14
0 1(1 ±1 _ 22112 _ 149 - 0.549 -
1 112—1 1 23112 10 135 -14 0.520 -29
2 116 —3 5 23615 15 128 -21 0.503 -46
5 115±3 4 24514 24 132 -17 0.539 -10
10 117±2 6 25715 36 118 -31 0.505 -44
IS 11i±3 5 27212 51 118 -31 0.535 -14
20 115 ^2 4 28617 65 104 -45 0.496 -53
25 1H±2 5 29413 73 103 -46 0.505 -44
30 115 *3 4 29912 78 100 -49 0.498 -51
Dog 4.
T ine PR1SD APK QliSD A(H HR A HR QT/JtR A Ql/RR
(nins) Knsec) (nsec) (nsec) (nsec) (bt/nin)
0 11315 _ 24115 _ 128 0.514
1 11413 1 24713 6 128 - 0.527 13
2 11414 1 26615 25 123 -5 0.545 31
5 11415 1 28515 44 115 -13 0.546 32
10 11713 4 30112 60 111 -17 0.557 43
15 11712 4 31814 77 100 -28 0.530 16
0 11313 - 24016 - 156 _ 0.624
1 :11816 5 25012 10 116 -40 0.483 -141
2 11613 3 25313 13 136 -20 0.573 -51
5 11613 3 27815 38 134 -22 0.621 -3
10 11816 5 31519 75 119 -37 0.625 1
15 12011 7 34319 103 109 -47 0.623 -1
20 11613 3 35219 112 88 -68 0.657 33
25 11812 5 34919 109 105 -51 0.634 10
30 11712 4 33017 90 116 -40 0.638 14
140
Table D.
The effects of propranolol, infused at a rate of
0.067 mg/kg/min, on HR, PR and QT intervals and QT/RR ratio
in four conscious dogs. Each test was carried out in duplicate
and the two test runs are shown for each dog. Recovery
time of several days was allowed between tests. Where S.D.
values are shown, these are calculated from a 6-beat














A HR 0T/RR A 0T/RR
0 109 13 . 217 14 89 0.326
1 11011 1 22015 3 84 -5 0.310 -16
2 11815 9 22012 3 67 -22 0.246 -80
5 124 14 15 22813 11 75 -14 0.284 -42
10 128 14 19 227 1 4 10 86 -3 0.372 1
15 126 15 17 23415 17 76 -13 0.296 -30
23 12613 17 232 1 2 15 61 -28 0.235 -91
25 13316 24 230 1 3 13 71 -18 0.274 -52
30 131 12 22 23313 16 74 -15 0.287 -39
0 114 13 _ 20011 114 0.378
1 11512 1 204 1 2 4 112 -2 0£379 1
2 12314 9 206 1 4 6 106 -8 0.363 -15
5 12215 8 20616 8 99 -15 0.344 -34
10 14016 26 21012 10 ice -6 0.378 _
15 13917 25 214 13 14 87 -27 0.312 -66
20 13011 16 222 1 2 22 83 -31 0.308 -70
25 13616 22 224 14 24 73 -41 0.274 -104
30 129 11 15 221 12 21 90 -24 0.330 -48
Dog 2.
T i ne F&ISD a FK ffTiSD a G7 HR a hr (Tt/frfc a(TT/ITR
(nins) (nsec) (nsec ) (usee) (nsec) (bt/nin)
0 120 ±4 _ 23016 _ 113 _ 0.348 _
1 123 ±7 3 21511 -15 101 -12 0.361 1 3
2 12415 4 22111 -9 75 -3B 0.276 -72
5 12914 9 21013 -20 75 -38 0.261 -87
10 14 318 23 23112 1 82 -31 0.318 -30
15 HO 12 20 23916 9 83 -30 0.333 -15
20 'HO ±4 20 23218 2 86 -27 0.32? -17
25 13415 1 4 23714 7 87 -26 0.330 -18
30 4011 20 2 3017 0 88 -25 0.336 -12
0 1716 - 24817 - 78 - 0.323 -
1 12614 9 24614 -2 76 - 2 0.312 -1 1
2 12719 10 25614 8 64 -14 0.273 -50
5 13516 18 26414 16 60 -18 0.263 -60
10 HI 18 24 26616 18 59 -19 0.261 -62
15 13515 18 26417 16 61 -17 0.267 -56
20 13515 18 26418 16 68 -10 0.302 -21
25 14016 23 26413 16 72 -6 0.316 _ 1





T int FftlSD APi QT1S8 Off HR AHR QT/RR AQT/RR
(nint) nstc) (nstc) (nstc) (nstc) (bt/nin)
0 10? ±4 22714 _ 45 _ 0.244 .
1 107 14 2 22814 1 73 8 0.277 "31
2 113±5 4 22?+4 2 72 7 0.273 2?
5 112 ±3 3 22515 -2 47 2 0.251 5
to 112 ±5 3 23012 3 47 2 0.257 11
13 117*4 8 22812 1 80 13 0.304 58
20 12215 13 22513 -2 77 12 0.321 75
25 11?±8 10 22012 -7 78 13 0.284 40
30 122 ±4 13 22414 -3 81 14 0.302 54
0 '110 ±4 - 21 ?±4 _ ?4 _ 0.343 _
1 113+2 5 22214 3 84 -8 0.318 -23
2 11312 3 21818 -1 104 10 0.378 35
5 124+7 14 22514 4 43 -31 0.234 -107
10 131+5 21 22413 5 4? -25 0.258 -85
15 13313 23 2201? 1 80 -14 0.293 -50
20 1341? 24 21514 -4 90 -4 0.322 -21
25 13114 21 215±4 -4 82 -12 0.294 -4?















0 10714 _ 19714 _ 104 . 0.348 .
1 11413 7 19311 -2 110 4 0.357 9
2 11414 7 20013 3 110 4 0.347 19
5 11415 7 20111 4 104 -2 0.348 -
10 119+2 12 20213 5 102 -4 0.343 -5
t5 12414 17 19814 1 107 1 0.353 5
20 12114 14 20414 7 94 -10 0.324 -22
23 12111 14 20712 10 101 -5 0.348 -
30 124i2 1? 20314 8 98 -8 0.335 -13
0 111+3 . 21214 - 92 - 0.325 -
1 111+1 - 21514 3 94 4 0.344 1?
2 11413 5 21414 2 91 -1 0.325 -
5 121 H 10 21714 5 78 -14 0.282 -43
10 12313 12 21713 5 8? -3 0.322 -3
13 12? ±4 18 22512 13 77 -13 0.38? -34
20 12712 14 22314 11 82 -10 0.305 -20
23 131 ±2 20 22413 14 83 -9 0.313 -12
30 1 33±3 22 22313 13 82 -10 0.308 -17
±<±Z
Table E.
The effects of propranolol, infused at a rate of
0.067 mg/kg/min, on HR, PR and QT intervals and QT/RR
ratio in four conscious dogs pretreated with carbimazole.
Where S.D. values are shown, these ar<? calculated from














a HR QT/RR or/RR |
0 025*5
_
219*7 - 82 _ 0.209 _
1 114*8 -H 216*9 -3 54 -28 0.196 -93
2 134*6 -l 231*2 12 56 -27 0.213 -76
5 :127*6 2 223*5 4 66 -16 0.245 -44
10 ,133*3 5 220*4 1 73 -9 0.268 -21
15 138*4 3 221*4 2 84 2 0.310 21
23 134*6 3 224*4 5 66 -16 0.248 -41
25 133*5 3 21*5 -5 92 10 0.327 38














a m QT/RR a QT/RR
0 11712 - 22112 - 84 _ 0.329
1 12212 5 225 1 4 78 -6 0.292 -37
2 12614 9 23313 12 66 -18 0.257 -72
5 12514 9 22715 6 118 34 a 445 116
10 13212 15 23417 13 63 -21 0.245 -84
15 13513 18 23413 13 71 -13 0.276 -53
2D 13914 22 2U12 2D 61 -23 0.245 -84
25 13613 19 24014 19 71 -13 0.284 -45


















0 112 ±2 - 21»i5 - 94 - 0.32S -
1 114 ±2 2 216±3 6 80 -14 0.288 -41
2 117 ±3 5 21 ?±4 7 75 -1? 0.271 -58
5 12# ±2 8 21V±? 9 86 -8 0.31' -15
10 12613 14 221 ±2 1 1 78 -16 0.28/ -42
15 12812 16 22313 13 8? -5 0.331 7
20 13111 1? 22512 1 5 83 -1 1 0.311 -18
25 13113 1? 22113 I 4 79 -15 0.2V5 -34
















or /ftft A 01 / ft ft
0 112±3 - 228±3 1 00 - 0.380 -
1 113±2 1 22515 -3 10? ? 0.40? 29
2 117±3 5 22013 -8 93 -7 0.341 -3?
5 1 1813 6 23013 2 79 -21 0.303 -77
10 117-4 5 23412 6 79 -21 0.308 -?2
15 12312 1 1 23615 8 81 -1? 0.31? "0 i
20 12411 12 23111 3 86 -20 0.308 - 72
25 12315 11 23614 8 79 -21 0.31 1 -6?
30 12814 16 22313 -5 75 -25 1 .279 -101
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Table F.
The effects of propranolol, infused at a rate of
0.067 mg/kg/min, on HR, PR and QT intervals and QT/RR
ratio in four conscious dogs pretreated with triiodo¬
thyronine. Recovery time of several days was allowed
between tests. Where S.D. values are shown, these are
















0 I03H _ 22714 _ 141 _ 0.333 .
t I0T ±3 4 22713 119 -22 0.430 -83
2 iu *2 4 23H2 4 143 2 0.551 18
5 113*1 1 240H 13 121 -20 0.484 -49
10 114*3 9 24017 13 125 -14 0 .300 -33
IS J 13 ±3 10 24413 17 122 -19 0.494 -37
20 11413 9 24415 17 119 -22 0.484 -49
23 12012 15 24513 18 117 -24 0.478 -35
30 12713 15 23813 11 113 -28 0.448 -85
0 11413 23?H 145 . 0.581 -
t 11412 2 24812 9 144 -1 0.593 14
2 11813 4 25H2 12 135 -10 0.345 -14
5 ;11 812 4 24413 7 147 2 0.403 22
10 '11713 3 24212 23 128 -17 0.359 -22
13 11 814 4 23413 15 130 -15 0.530 -31
20 12413 12 252*1 13 141 -4 0.592 11
23 J 2513 11 24212 23 124 -21 0.541 -40
30 12413 10 25012 11 134 -9 0.347 -14-
Dog 2.
Tine Pli±SB 4 PR FTiSO a err HR *HR QI/RR QI/RR
(nint) <»«fC) (fitec) (fisec ) (nsec) (bt/tiin)
0 ?;±3 _ 20313 _ 172 _ 0.582 .
1 102-3 5 211*2 8 151 -21 0.531 -51
2 .102-2 5 224*4 21 141 -31 0.324 -54
5 111-1 14 235*4 32 129 -43 0.505 -77
10 112^2 15 235*4 32 130 -42 0.509 -73
13 111 ^3 14 237*4 34 128 -44 0.504 -74
20 114-1 17 237*2 34 134 -38 0.329 -53
25 110^1 13 234*4 33 134 -38 0.527 -55
30 121 ±1 24 235*5 32 129 -43 0.305 -77
0 110±2 _ 231 ^4 - 142 - 0.547 -
1 111 ±2 1 234 *5 3 148 4 0.577 30
2 I 13±2 4 239*1 8 132 -10 0.524 -21
3 1U±2 5 242*3 11 134 -8 0.540 -7
10 jl 1 B 14 7 234*3 3 135 -7 0.531 -14
13 ,120H 10 23713 4 150 8 0.592 45
20 120—1 10 23514 4 141 -1 0.552 5
25 121 13 11 237*2 4 140 -1 0.553 6
















AHR or/RR A OT/RR
0
... ,
116 ±9 _ 21316 _ 107 _ 0.390 _
1 11616 - 238 1 6 25 98 -9 0.390 -
2 13118 15 236 1 5 23 96 -11 0.377 -13
5 11814 2 24113 28 104 -3 0.416 26
10 11712 1 234 1 4 21 104 -3 0.405 15
15 12116 5 234 1 7 21 99 -8 0.388 -2
20 12314 7 22717 14 107 - 0.404 14
25 11915 3 239 1 5 26 93 -14 0.369 -21
30 12315 7 222 1 4 9 96 -11 0.355 -35
0 10614 229 1 5 140 0.535 _
1 10714 2 23016 1 156 15 0.596 61
2 |L16!4 11 23216 3 124 -16 0.480 -56
5 11714 12 23014 1 147 7 0.564 29
10 11416 9 22314 -6 170 30 0.633 98
15 jll4 14 9 230 1 6 1 148 8 0.567 32
20 114 16 9 222 1 2 -7 143 3 0.530 -5
25 CL16 14 11 225 1 5 -3 160 20 0.604 69
30 [11713 12 22914 - 157 17 0.601 1 66
Time PR ±SD a PR QTlSD a or HR a HR QT/RR a OT/RR
(mins) (msec) (msec) (msec) (msec) (bts/min)
0 10614 - 22914 _ 126 0.478
1 10712 1 22112 -8 146 20 0.537 59
2 10216 -4 21614 -13 150 24 0.541 63
5- 11112 5 223 1 7 -6 124 -2 0.460 -18
10 11412 8 22714 -2 131 5 0.496 18
15 119 14 13 24517 16 112 -14 0.456 -22
20 12013 14 249 ±9 20 110 -16 0.457 -21"
25 12414 18 259 1 8 30 111 -15 0.477 -1
30 124 ±4 18 25111 32 103 -23 0.450 -28
0 11013 - 282 1 9 _ 111 0.524
1 10614 -4 252 1 6 -30 145 34 0.540 14
2 10713 -3 254 ±12 -18 156 45 0.684 160
5 :11313 3 219110 -63 119 8 0.434 -90
10 11113 1 225112 -57 145 34 0.544 2U
15 11816 7 251121 -81 132 21 0.553 29
20 11914 9 27119 -11 124 13 0.560 36
25 113111 3 268111 -14 114 3 0.507 -17
30 122:114 11 252114 -30 125 14 0.523 -1
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Table G.
The effects of nadolol, infused at a rate of 0.167 mg/kg/min,
on HR, PR and QT intervals and QT/RR ratio in two conscious
dogs. Where S.D. values are shown,these are calculated from













6 HR if/RR &qf/RR
0 112*2 - 210*2 - 104 - 0.364 _
1 119*4 7 21112 1 39 -lb 0.313 -51
2 11,"±5 5 213*4 3 91 -13 0.323 -41
5 11715 5 223*4 13 97 -7 0 . jiOC -4
10 113 .< 219*2 19 93 -11 0.336 -25
15 11213 4 219*3 19 94 -10 0.343 -21
20 115*5 3 217*2 17 94 -10 0.340 -24
0 11-13 - 237*2 - 53 _ 0.249 _
1 11911 8 244*4 7 70 7 0.285 36
2 12012 9 254*4 17 61 -2 0.258 0
5 12013 0 253*2 16 58 -5 0.245 -4
1J 112*4 1 24512 9 89 6 0.265 34
110*2 -1 262*5 25 51 -12 0.223 -25
20 11413 3 24912 12 66 3 0.274 25
Table H.
The effects of nadolol, infused at a rate of 0.167 mg/kg/min,
on HR, PR and QT intervals and QT/RR ratio in two conscious
dogs pretreated with carbimazole. Where S.D. values are
shown, these are calculated from a 6-beat sample of the
ECG record at the time stated.
Dog 1.
Dog 2.
Time PR ±SD A PR qT±Su A qr KR AKH ;T/I« S.qT/RR
:.1 i n5 ) (mGec) (msec] (msec) (usee) (btB/min)
0 114 £2 - 205*4 - 98 - 0.336 -
1 11214 -2 20911 3 95 -3 c V V-M -5
11ol5 2 21'0*1 4 95 -5 0.32s
-10
3 115*5 1 213*3 -3 43CO -12 0.305 -31
10 114*3 - 22012 2 •;8 - 0.340
4
15 115*3 1 209*4 3 101 0.352
15
20 Ho*; 4 204±3 -2 91 -7 0.309 -27
2 11 .±2 - 20i±3 - 105 6 0.354 2 ■
.1 114 *4 . 214*4 _ 33 - 0.314
-
1 11 *> - 217*6 3 88
- 0.31.. 4
*3 11 *5 4 226*5 1s 6U
-I* 0.3'V 5
1 i4*j - 231*1 1? 70 -1 .1.2/0
-44
1 ;• -1 251*2 17 o'» 0.323 ■
1. 117*4 3 2. 413 20 79 -9 0.303
-6
'0 115*5 -1 727*3 15 >2 0.310
25 112*1 - 23J*1 v.-2 -0 0.^14
-
50 11 .12 -1 723*4 V» .51, 5
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Table I.
The effects of nadolol, infused at a rate of 0.167 mg/kg/min,
on HR, PR and QT intervals and QT/RR ratio in two conscious
dogs pretreated with triiodothyronine.*Where S.D. values
are shown, these are calculated from a 6-beat sample of













A HR ■ir/RR Air/RR
0 108t4 _ 233fc1 - 129 - 0.501
1 112fc2 't 232+5 -1 148 19 0.572 71
2 114i2 6 244t2 11 147 18 0.598 97
5 11213 4 2^-7+4 If 147 16 0.581 06
1 0 111+2 3 227+3 -6 143 14 0.541 40
15 112+3 if 233+If 5 139 10 0.551 50
20 111±8 3 259+3 26 88 -41 0.380 -121
110+4 2 2'i7+3 1 if 108 -21 0.445 -56
>0 112+1 1 24at3 15 94 -35 0.333 -113
0 110+2 _ 242+5 _ 157 - 0.655 -
1 112+2 2 239+2 -3 143 -14 0.570 -63
2 11 ii't 9 257*2 15 129 -28 0.552 -81
5 » 115±1 5 266+3 2lf 131 -26 0.501 -52
10 l1o±5 3 266+6 2lf 133 -19 0.612 -21
15 118±3 3 27042 26 124 -33 0.558 -75
20 n&t3 3 260t3 24 125 -32 0.554 -79
25 110±3 6 2o7t2 25 130 -27 0.573 -55
30 110+5 - 256+3 24 125 -32 0.554 -79
148
Table J.


























































































Equipotent Molar Ratios (EMR) are calculated with respect to Isoprenaline (1)
Figures in brackets Indicate number of estimates.
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